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ABSTRACT 
 
 
  The dissertation is focused on the evaluation of a Docetaxel-based 
sequential regimen as adjuvant therapy of breast cancer.  
Docetaxel is among the most active chemotherapeutic agents for breast 
cancer. With Taxit 216 trial, we aimed to assess the efficacy of adding 
docetaxel in a block-sequential fashion to a regimen with doxorubicin followed 
by CMF in the adjuvant therapy for node-positive early stage breast cancer 
(ESBC). 
Patients were randomized to arm A (epirubicin 120 mg/m2 for 4 cycles then  
cyclophosphamide, methotrexate and 5-fluorouracil [CMF] for 4 cycles), or 
arm B (4 cycles of docetaxel 100 mg/m2 administered after the fourth 
epirubicin cycle and before the first CMF cycle).  Treatment allocation was 
performed, in our Institution,  by a computer program using a minimization 
algorithm. Stratification factors were: center, lymph node involvement (1 to 3, 
4 to 9, >10), estrogen receptor status (negative/positive/unknown), menopausal 
status (pre/post). The primary end-point was invasive disease-free survival 
(IDFS). Secondary end-points were recurrence-free survival (RFS), overall 
survival (OS) and toxicity. The study was designed to detect a hazard ratio of 
0.70, assuming an α of 0.05 (two-sided), a power of 0.80 and an expected DFS 
in arm A of 0.65 at 5 years. This required 480 patients per arm and 250 events. 
Final results are reported according to the standardized system for efficacy end 
points (STEEP system). 
Between July 1998 and July 2002, 972 patients were randomized (486 in 
each arm). At a median follow-up of 62 months, 278 IDFS events were 
recorded. Five-year IDFS was 74% in arm B vs 68% in arm A (P = 0.13), with 
a hazard ratio (HR) of 0.82 (95% confidence interval [CI] = 0.64–1.03). RFS 
was significantly better for arm B than for arm A (76% vs 69%; P = 0.0332) 
with a HR of 0.75 (95% CI = 0.59–0.96). There was a significant improvement 
in OS, with an estimated five-year OS of 90% in arm B and 85% in arm A (P = 
0.0168; HR = 0.67, 95% CI = 0.48–0.94). This benefit comes at the cost of 
increased but acceptable toxicity.  
We demonstrated, with the results of the Taxit 216 phase III trial, that  
incorporating docetaxel into a block-sequential epirubicin–CMF regimen 
significantly reduces the risk of recurrence and death in patients with node-
positive ESBC.  
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1  INTRODUCTION 
 
 
1.1 Adjuvant chemotherapy 
 
An overview, carried out in 1998 by the Early Breast Cancer Trialists’ 
Collaborative Group, of all randomized trials performed worldwide 
demonstrated that adjuvant chemotherapy reduces risk of recurrence and death 
of operable early stage breast cancer (ESBC) (EBCTCG 1998). The overview 
also showed that anthracycline-based combinations are generally more 
effective in ESBC than earlier combinations, like cyclophosphamide-
methotrexate-fluorouracil (CMF); in fact, there was an additional reduction in 
the annual breast cancer relapse rate of 12% and of the annual death rate of  
11% versus CMF. These findings encouraged the diffusion of anthracycline-
based regimens but, in the absence of direct comparison between different 
anthracyclines-based schedules, different regimens were adopted worldwide, 
based on local preference. 
In this scenario, a sequential regimen consisting of 4 courses of doxorubicin 
followed by various courses of CMF gained widespread acceptance in Europe. 
This was fuelled by the results of a randomized trial by Bonadonna et al 
(Bonadonna et al 1995, Buzzoni et al 1991), in which this block-sequential 
regimen compared favorably with a regimen alternating doxorubicin and CMF 
courses. This observation was also consistent with mathematical models that 
predicted better outcomes with block-sequential therapy than with an 
alternating regimen of non-cross-resistant agents (Norton and Simon 1986). 
Therefore, despite the lack of trials directly comparing the block-sequential 
therapy with the classical CMF, this regimen was regarded as a standard 
treatment by many clinicians in Europe and was, thus, chosen as standard 
reference arm by the Taxit 216, designed by Italian investigators in 1998 in the 
attempt to improve the efficacy of a standard adjuvant chemotherapy for node-
positive early stage breast cancer. Nonetheless, the superiority of the block-
sequential regimen over classical CMF has been more recently demonstrated 
for both anthracycline compounds, doxorubicin (De Placido et al 2005) and 
epirubicin (Poole at al 2006), thus providing further support to the reference 
arm in our trial.  
In the Taxit 216 we aimed to assess the efficacy of adding docetaxel to a 
sequential anthracycline-based regimen in the adjuvant therapy for node-
positive early stage breast cancer (ESBC). In accordance with the Norton-
Simon model (Norton and Simon 1986), this regimen should warrant the 
highest dose-intensity for each drug used at standard dose while theoretically 
limiting the increase of toxicity, thus possibly yielding the best chance of 
tumor eradication. 
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1.2 Taxanes 
 
In the late 1960's the National Cancer Institute's large-scale plant screening 
program found that a crude extract of the bark from the Pacific yew, Taxus 
brevifolia had activity against the P388 mouse leukemia. In 1971, Wani, 
Taylor et al (Wani et al 1971) isolated and characterized Taxol (paclitaxel), the 
active principle of the extract. Subsequent research showed that paclitaxel has 
activity against several human malignancies including refractory ovarian 
cancer and breast cancer (Holmes et al 1971) and Taxol (Bristol Myers 
Squibb) is now approved for use in these indications in some countries. 
Several years ago, researchers at Rhône-Poulenc Rorer, with the co-
operation of the French "Center National de Recherche Scientifique (CNRS)", 
were able to prepare docetaxel, a semisynthetic analog of paclitaxel, using a 
precursor extracted from the needles of the European yew, Taxus baccata. 
Docetaxel was shown to have superior in vivo antitumor activity as compared 
to paclitaxel in the B16 melanoma model (Bissery et al 1990). Docetaxel also 
has a slightly better solubility than paclitaxel. Its toxicity profile in animals 
was favorable, and it has subsequently been undergoing development in an 
international human clinical trial program. Development has reached the stage 
of phase II/III clinical trials and has shown favorable response rate in breast 
cancer. 
 
 
1.3 Docetaxel 
1.3.1 Name and chemical information 
- Docetaxel, (RP 56976) 
 
- Chemical name: 4-acetoxy-2a-benzoyloxy-5b, 20 -epoxy-1, 7b, 10b-
Trihydroxy- 9-oxotax-11 -ene- 13a-yl -(2R, 3S)-3-tert-
butoxycarbonylamino-2-hydroxy-3-phenylpropionate 
 
- Chemical structure: 
 
                             
o
HN
o
o
HO
HO
o
o
o
o
o
HO
HO
o
o
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- Empirical formula: C43H53O14N, 3 H2 O 
- Molecular weight: 807.9 
- Appearance: White powder 
- Solubility at 20°C: water practically insoluble 
 
1.3.2  Mechanism of action 
Docetaxel has a mechanism of action which is similar to (or may be 
identical to) paclitaxel (Bissery et al 1990). Docetaxel enhances microtubule 
assembly and inhibits the depolymerization of tubulin. As with paclitaxel, this 
can lead to bundles of microtubules in the cell, which by blocking cells in the 
M phase of the cell cycle results in the inability of the cells to divide. This 
contrasts with the action of other spindle poisons in clinical use such as 
colchicine or vinca-alkaloids which inhibit tubulin assembly in microtubules. 
Comparing paclitaxel and docetaxel using the "tubulin in vitro assay", the 
concentration required to provide 50% inhibition of microtubule disassembly 
(or IC50) for docetaxel is 0.2 µm and for paclitaxel is 0.4 µm. 
 
1.3.3 Experimental antitumor activity 
Docetaxel has been tested against tumors representing a variety of tissue 
types and behavioral patterns. It is highly active against B16 melanoma. The 
total log cell kill is 2.5 times greater for docetaxel than for paclitaxel, at 
equitoxic dosages in this model. Docetaxel is active against three colon 
tumors: C38, C51 and C26, and causes complete regression of advanced stage 
colon adenocarcinoma C38. It also causes complete regression of advanced 
stage pancreatic adenocarcinoma P03. Docetaxel exhibits cross resistance to 
pleiotropic resistant cell lines. Docetaxel is considered as a schedule 
independent drug: anti-tumor activity correlates with the total dosage that can 
be administered and dose-splitting does not appreciably change efficacy. 
 
1.3.4 Human pharmacokinetic data 
The docetaxel kinetic profile is consistent with a three-compartment 
pharmacokinetic model independent of administration schedule or dose, 
although the terminal elimination phase can not always be observed i.e. at low 
doses and/or for some administration schedules because of the low plasma 
levels achieved. No evidence of dose-dependence of docetaxel clearance (CL) 
was observed following either 1-2 hour (TAX 001) or 6 hours (TAX 004) 
infusions. Typical drug exposure following 1 hour infusion of 100 mg/m² is 
(TAX 006 study) : 
- Peak: 3.67 µg/ml 
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- AUC: 4.59 µg.h/ml 
Mean pharmacokinetic parameter estimates are (TAX 001 and TAX 006 
studies, population analysis): 
- t1/2 : 4 min 
- t1/2 : 36 min 
- t1/2 : 11.1 h 
- CL : 35.3 l/h (21.0 l/h/m²) 
- Vss : 113 l (67.3 l/m²) 
Docetaxel is extensively bound to plasma proteins. In vitro the plasma 
protein binding is 93-94 % whatever the drug concentration. The main proteins 
involved are albumin, 1-acid glycoprotein and lipoproteins. A binding of 
97.8% was measured in vivo in 3 cancer patients. None of the anticancer drugs 
studied nor dexamethasone were found to displace docetaxel binding. 
After infusion of 14C-docetaxel (100 mg/m² in 1 hour), excretion occurs 
mainly in the feces (75% of the dose) mostly during the first 48 hours post 
dosing. Urinary excretion accounts for only 5% of the dose. Docetaxel is 
extensively metabolized and unchanged drug represents a small fraction of the 
radioactivity excreted. However, most of the circulating radioactivity is 
accounted for by unchanged docetaxel, and no circulating metabolites could be 
detected in plasma. The main metabolic pathway for docetaxel metabolism in 
humans as in animal species consists of successive oxidations (alcohol, 
aldehyde, acid) of the tert-butyl ester group on the side chain. 
A sparse sampling strategy aiming at defining the docetaxel kinetic profile 
over a population of patients and assessing docetaxel population PK/PD was 
implemented in 22 Phase II multi-centric studies (577 patients). Population PK 
analysis demonstrated that inter-patient variability of docetaxel clearance is 
significantly related to body surface area, age, 1-acid glycoprotein and albumin 
plasma levels and hepatic enzyme plasma levels. The presence of liver 
metastases per se was not found to alter clearance. Likewise, clearance was not 
found to differ between male and female patients. PK/PD analysis (logistic 
regression model) using estimates of individual patient CL demonstrated that, 
after adjustment for the effects of other covariates, CL variability is a strong 
predictor of the odds of Grade 4 neutropenia. 
 
1.3.5 Efficacy in advanced breast cancer 
Taxanes were introduced for treatment of advanced breast cancer in the 
1990s and their potential utility as adjuvant therapy was well acknowledged in 
1998. Docetaxel, in particular appeared to be highly effective compound as 
monochemotherapy in the treatment of metastatic breast cancer and its activity 
in anthracycline-resistant disease was well defined.  
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Phase II studies showed a response rate raging from 48.2% in anthracycline 
resistant patients to 38.8% in anthracycline refractory patients (Valero et al 
1995; Ravdin et al 1995). These data were confirmed by the phase III studies 
conducted in anthracycline failure patients (Chan et al 1999, Paridaens et al 
2000, Sledge et al 2003). Infact, two international  phase III  studies were 
conducted to compare the antitumor activity of taxotere administered as 
monotherapy, to doxorubicin and to a combination of mitomycin C and 
vinblastine respectively (study 303, 304) (Nabholtz et al 1999). Three hundred 
and twenty-six patients with metastatic breast cancer who  failed previous 
alkylating agents entered in study 303; 161 patients were randomized to 
receive 100 mg/m2 taxotere every 3 weeks and 165 patients received 75 mg/m2 
of doxorubicin every 3 weeks. Both drugs were administered for a maximum 
of 7 cycles. The main patient characteristics (median age, performance status, 
previous hormonal treatments and previous response to alkylating agents, site 
of disease, and number of sites involved) were well balanced in the two 
treatment groups. In the intention to treat population  the overall response rate 
(ORR) is significantly higher  (P <0.004) in taxotere group (47%) with respect 
doxorubicin group (32%) with 8.1% CR in taxotere group vs 4.2% in 
doxorubicin group. An earlier onset of the response was observed in taxotere 
treated patients 13 wks (range for the responders 3 - 51 ) vs 23 wks (range for 
the responders 3 - 23) in doxorubicin patients. Higher response rate was 
observed in patients resistant to alkylating agents, 43% in taxotere group vs 
21% in doxorubicin (P< 0.003) and  with  visceral metastases (46% in taxotere 
group vs 28% in doxorubicin group P< 0.003). The difference between the 2 
treatment groups was particularly striking in the subgroup of patients with liver 
metastases; a response rate of 57% was achieved in taxotere treated patients 
whereas only the 23% of patients responded in doxorubicin group (P< 0.001). 
To date, no sufficient events are available to conduct the analysis on TTP and 
survival. The median number of cycles administered were 7 in taxotere group 
and 6 in doxorubicin group with a median relative dose intensity (RDI) of  0.97 
(0.05-1.07) for taxotere and 0.95 (0.49-1.05) for doxorubicin. Three hundred 
and twenty-two patients out of 326, 159 in taxotere arm and 163 in doxorubicin 
arm were evaluable for safety. Two patients in each group were randomized 
but did not receive the treatment. The 12 % and the 14% of the patients 
discontinued the study drug  for  adverse events in taxotere and doxorubicin 
group respectively. The study drug assigned was discontinued for cardiac 
toxicity in all patients in doxorubicin group, whereas in taxotere group 
neurological toxicity and fluid retention leaded to drug discontinuation in 7 and 
3 patients respectively. Treatment discontinuation for  death occurred in  5  
patients (3%)  in taxotere  and in 4 patients (2%) in doxorubicin group. One 
septic death occurred in both groups; 2 and 1 patients died of unrelated events 
in taxotere and doxorubicin group respectively. All the other deaths were due 
to progressive disease. The most frequent adverse event reported in both arms 
was neutropenia. No significant differences were reported about the incidence 
of this side effect (97.4% and 96.7%) including  grade 3 and 4 episodes (grade 
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3 - 14.4% vs 10.6%; grade 4 - 78.4% vs 78.1%) in taxotere and doxorubicin 
treated patients. The percentage of febrile neutropenia was significantly higher 
P< 0.04 in doxorubicin arm 12.3% with respect taxotere 5.7% as well as the 
incidence of thrombocytopenia 39.4% vs 3.8%, although the incidence of grade 
4 thrombocytopenia was low in both groups (1.3% vs 7.5% in taxotere and 
doxorubicin arm respectively). The main grade 3 and 4 non hematological side 
effects experienced by patients in taxotere group versus doxorubicin group 
were: nausea 2.5% vs 14.1%; vomiting 2.5% vs 11.7%; diarrhea 10.7%  vs 
1.2%; stomatitis 5% vs 11.7%; asthenia 13.8% vs 11.7%. Severe fluid retention 
and neurosensory disorder occurred in 5% of patients treated with taxotere no 
death related to these adverse events were reported; 3.1% of patients in 
doxorubicin group experienced cardiotoxicity which was responsible for 2 
deaths. Three hundred and ninety-two patients with metastatic breast cancer 
who failed previous anthracycline agents entered in study 304. Two hundred 
and two patients were randomized to receive 100 mg/m2 taxotere every 3 
weeks and 190 patients received a combination of Mitomycic C 12 mg/m2 
every 6 weeks and vinblastine 6 mg/m2 every 3 weeks (MV). A maximum of 
10 cycles were recommended in responding patients while 6 cycles were 
foreseen in patients with stable disease. Preliminary results on 105 patients of 
taxotere arm and on 95 patients MV arm are available. No differences were 
found for the main patient characteristics between taxotere and MV patients 
(median age 50 (30-73) vs 50 (33-73), performance status 90 (60-100) vs 90 
(60-100), previous hormonal treatment 65% vs 68%, previous response to 
anthracycline (not resistant 33% vs 39%; primary resistant 25% vs 19%; 
secondary resistant 42% vs 42%), site of disease (visceral 74% vs 73%; bone 
52% vs 63%; visceral plus bone 17% vs 20%; visceral plus bone plus soft 
tissue 21% vs 24%), and > 3 sites involved 41% vs 52%). The preliminary 
analysis was conducted both in all randomized patients and on 
eligible/evaluable patients.In the randomized population the overall response 
rate (ORR) is higher in taxotere group 28%  with respect in MV group  13%. 
The same ratio of difference is confirmed  in evaluable population (28% vs 
14% in taxotere and MV group respectively). A CR was achieved in  the 5% of 
patients treated with taxotere and 2% of patients of MV arm. The higher 
response rate was observed in patients with bidimensionally measurable 
disease 32% in taxotere arm whereas in MV arm no major difference with 
respect the ORR were observed (12%). The median number of cycles 
administered were 6 (range 1-12) in taxotere group and 3 (range 1-10) in MV 
group with a median RDI of 0.96 for taxotere patient, 0.99 for Mitomycin C 
and 0.98  for Vinblastine. A hundred and ninety-four patients; 104 in taxotere 
arm and 94 in MV arm were evaluable for safety. One patient in each group 
was randomized but did not receive the treatment. Ten % and the 14% of the 
patients discontinued the study drug for adverse events in taxotere and MV 
group respectively. The 7% of patients withdrew MV treatment for 
thrombocytopenia whereas the 6% of patients discontinued the taxotere 
treatment for fluid retention. Death occurred in 6.7% of patients in taxotere and 
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in 6.3% of patients in MV group. One septic death and 1 death due to 
unexplained respiratory failure occurred in taxotere group while 1 death due to 
hemolytic uremic syndrome occurred in MV group. One patient in each group 
died of unrelated event. All the other deaths were due to progressive disease. 
The most frequent adverse event reported in  both arms was neutropenia 98% 
and 87.5% in taxotere and MV arms respectively. Grade 3/4 episodes occurred 
in 88.8% of patients treated with taxotere and  in 67% of patients treated with 
MV. The percentage of febrile neutropenia was higher in taxotere arm (10.6%) 
with respect MV arm (1.1%), while thrombocytopenia was higher in MV group 
(35.9%) with respect taxotere group (8.7%) including grade 3/4 episodes 12% 
in MV vs 5.8% in taxotere group. The main grade 3 and 4 non hematological 
side effects experienced by patients in taxotere group versus MV group were: 
diarrhea 8.6% vs 0%; stomatitis 11.5% vs 1.1%; asthenia 16.3% vs 8.5%, 
constipation 0.9% vs 6.4%; pulmonary disorder 2.9% vs 6.4%; fluid retention 
9.6% vs 0%. 
Furthermore, the combination of anthracyclines and taxanes resulted in a 
better response rate and, in some cases, a longer time-to-progression than 
standard anthracycline-based regimens. Consequently, taxane-anthracycline 
combinations are now widely used as standard first-line treatment for advanced 
breast cancer. 
 
1.3.6 Anthracycline/Docetaxel cross-resistence 
In vitro, Docetaxel has been described to be recognized by the P. 
Glycoprotein. In addition, it has been established that docetaxel had IC50 
(reducing survival by 50%) value identical on 6/11 tumor cell lines 
overexpressing the mdr gene. On the other hand, a docetaxel resistant human 
cancer cell line were isolated by Arioka. This investigator reported that no 
cross resistance was observed to doxorubicin and etoposide when exposing this 
human lung adenocarcinoma cell line to these drugs. 
In vivo, in terms of patterns of cross resistance with other antitumor agents, 
cross resistance to docetaxel has been observed in multidrug resistant sublines 
such as P388/doxorubicin, CEM/VLB 1000, MCF-7/VCR GE and the 
CHO/CHRC5. However, these results must be looked at with caution since 
P388 is poorly sensitive to docetaxel and as P388 / doxorubicin and P388/VCC 
express high levels of mdr which may not be relevant to the clinical situation. 
Recently, and in order to investigate and to better understand a possible 
clinical cross resistance to docetaxel, Mc Bissery has developed a docetaxel 
resistant mouse B16 melanoma model, after 17 months and 27 passages of 
repeated exposure to IV Taxotere at the maximum tolerated dose (60 mg/kg) 
(Bissery et al 1990). The B16/TXT melanoma was found cross resistant to 
vincristine and vinblastine while only partial cross resistance to doxorubicin 
was noted. (B16/TXT = 0.9 log cell kill and B16 = 2.4 log cell kill). 
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In addition, no cross resistance was observed with the other tested drugs 
(cyclophosphamide or etoposide). 
Based on the above in vitro and in vivo data, cross resistance to PgP 
expressing cancer lines is partial in Taxotere resistant cell lines and in Taxotere 
resistant transplantable tumors and there is apparently no or only a partial cross 
resistance to doxorubicin. 
There are several clinical data suggesting at least a partial non cross 
resistance for doxorubicin and docetaxel. 
Three studies (two american and one european studies) were prospectively 
conducted in anthracycline resistant patients with metastatic disease. Their 
results confirm the preclinical data already reported. Two american studies 
(TAX 233 and TAX 267) were conducted in anthracycline/anthracenedione 
primary resistant (refractory) and secondary resistant patients. Overall 83 
patients were recruited and 80 patients were considered resistant: 60 to 
doxorubicin and 20 to mitoxantrone. The third study (TAX 286) is an european 
study conducted in strictly defined anthracycline primary resistant (refractory) 
patients. Fifty-one patients were treated. In these 3 studies, the following 
resistance definitions were used: 
- anthracycline/anthracenedione primary resistant patients were patients who 
progressed during an anthracenedione/anthracycline regimen or those who 
developed metastatic disease while still receiving adjuvant chemotherapy with 
anthracycline/anthracenedione containing regimen, 
- or those who had an initial response and then progressed while still 
receiving this treatment. Those patients are considered as secondary resistant. 
It is to be noted that no patients in Tax 286 experienced a response (CR or 
PR) to a prior anthracycline containing regimen, whereas 9 patients (15%) in 
Tax 233 and 267 had a prior objective response before progressing under the 
same anthracycline containing regimen. Among the anthracycline resistant 
patients, 94% in Tax 286 and 82% in Tax 233 and 267 represented the poorest 
population since either they did not experience any response to an 
anthracycline containing regimen and progressed during anthracycline or 
developed a relapse during an adjuvant chemotherapy. This population which 
has been prospectively recruited in Tax 286 and retrospectively analyzed in 
Tax 233 and 267 has been defined as "anthracycline refractory" to identify a 
subgroup with a  worse prognosis. 
Patients treated in Tax 286 had very aggressive disease associated with poor 
prognostic factors: 63% were less than 50 years of age; the median time 
between the first histological diagnosis and first study drug infusion was only 
25 months; 67% had at least one visceral site of disease involvement (43% had 
liver involvement and 33% had lung involvement); 98% patients had distant 
metastases and only one patient had locoregional disease; 41% of patients had 
more than two organs involved ; and 82% had received a prior chemotherapy 
for metastatic disease and 49% had received 2 prior regimens of chemotherapy 
(one with adjuvant intent and one for metastatic disease). 
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The incidence of the relevant prognostic factors of patients treated in Tax 
286 and in Tax 233 and 267 (table 2) are quite similar except for the age at 
study entry. Patients in Tax 286 were younger (62.7% < 50 years old) than 
those in Tax 233 + 267 (43.4% < 50 years old). In addition, 20 out of 39 
patients of Tax 286 with data on receptor status were negative for both 
estrogen and progesterone receptors.  
This last observation along with both a short median time between the first 
histological diagnosis and the first infusion of study drug (25 months vs 34 
months in Tax 267 and 20 months in Tax 233) and a stricter definition of 
anthracycline resistance in Tax 286 (i.e., primary resistant or refractory 
patients) suggest a worse prognosis for patients treated in Tax 286 in 
comparison to those treated in Tax 233 and 267. 
As expected, a lower response rate was observed in Tax 286 (29.4%, intent-
to-treat analysis; 31.6%, evaluable patients analysis) than that observed in Tax 
233 (46.3%, intent-to-treat analysis; 54.5% evaluable patients analysis) and in 
Tax 267 (50% and 57.1%, respectively). The difference observed could be 
related to the aforementioned worse prognosis of the patients recruited in Tax 
286: no patients had a response (CR, PR) to a prior anthracycline containing 
regimen; the majority of them were < 50 years old; a considerable number of 
patients were negative for both estrogen and progesteron receptors; a short 
median interval time was detected between the first histological diagnosis and 
the first study drug infusion. All these factors suggest a rapid evolution of the 
natural history of the disease. To further support this hypothesis, it is to be 
noted that, in Tax 286, a higher response rate was observed in the evaluable 
patient subgroup > 50 years old (46.6%) compared to the patient subpopulation 
aged < 50 years (21.7%). 
Again a lower response rate was observed among the patients in Tax 286 
when calculated by prognostic factors. However, when the results of the 3 
anthracycline resistant studies were pooled, the response rates among patients 
with visceral metastases (43.4% out of 76 evaluable patients), liver metastases 
(30.7% out of 39 evaluable patients), > 3 organs involved (48% out of 50 
evaluable patients), and baseline performance status of 2 as per WHO scale 
(42.8% out of 14 evaluable patients) were remarkable for a single agent in an 
anthracycline resistant (both primary and secondary resistant) patient 
population. 
Although all the aforementioned median times in Tax 286 are slightly 
shorter than those observed in Tax 233 and 267, the results of Tax 286 can still 
be considered remarkable for monochemotherapy in a patient population with 
very aggressive disease.  
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2   AIMS OF THE STUDY 
 
 
The results of the phase III trial in advanced breast cancer prompted 
randomized trials designed to evaluate the effect of taxanes, combined with or 
in sequence with anthracycline-based regimens, in the adjuvant treatment of 
EBSC patients. 
The Taxit 216 multicenter phase III trial was designed in 1998; we aimed to 
assess the efficacy and the toxicity of including docetaxel in a block-sequential 
fashion to a regimen with doxorubicin followed by CMF in node-positive early 
breast cancer patients. 
In details, were selected primary and secondary objectives. 
 
Primary objectives: 
• to compare the disease free survival (DFS) in patients treated with the 
sequential epidoxorubicin CMF regimen to that in patients treated with the 
same treatment plus docetaxel given sequentially after epidoxorubicin. 
 
Secondary objectives: 
• to evaluate the overall survival in each arm; 
• to compare the safety of a sequential epidoxorubicin→docetaxel→CMF 
(arm B) regimen versus a standard sequential epidoxorubicin→CMF (arm A). 
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3   MATERIALS AND METHODS 
 
 
3.1 Eligibility 
 
Eligible women were aged between 18 and 64 years and had undergone 
primary surgery with clear margins (modified mastectomy or tumorectomy) 
plus axillary dissection for histologically proven unilateral carcinoma of the 
breast (stage II-IIIa). Randomization was required within 6 weeks after breast 
cancer surgery. In the original protocol, eligible women had at least four 
positive axillary lymph nodes (of a minimum 10 nodes examined).  
The protocol was amended one year after trial onset to allow inclusion of 
patients with 1–3 positive nodes and up to 70 years of age. Other eligibility 
criteria were baseline left ventricular ejection fraction above the lower normal 
limit of each participating institution and adequate hematologic (granulocyte 
count  2x109/L, platelet count  100x109/L), hepatic (transaminases  1.5 x 
the upper limit of normal [ULN], alkaline phosphatases  2.5 x ULN, and 
bilirubin  ULN) and renal (serum creatinine  140 µmol/L [1.6 mg/dl] or 
creatinine clearance  60 ml/min) function.  
Mayor exclusion criteria included pregnancy, documented history of cardiac 
disease contraindicating anthracyclines, previous cancer (except treated basal-
cell and squamous-cell carcinoma of the skin or cancer of the uterine cervix), 
peripheral neuropathy > grade 2 according to the National Cancer Institute 
Common Toxicity Criteria (NCI-CTC) version 2, and previous radiation 
therapy, hormone therapy, or chemotherapy for breast cancer.  
Potentially eligible patients were staged by bone scan, chest x-ray, 
abdominal ultrasound, and contralateral mammography (Table 1).  
Estrogen receptor (ER) status was evaluated by immunohistochemistry with 
a cut-off of 10% of stained cells.  
Written informed consent was obtained before randomization.  
The protocol was reviewed and approved by ethics committees and 
institutional review boards of each center. The study was conducted according 
to the Declaration of Helsinki and European Good Clinical Practice 
requirements. 
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Table 1: Prestudy screen 
 
 INVESTIGATIONS TIMING 
 
History and 
physical 
exam 
Obtain patient informed consent 
History -including: diagnosis of breast adenocarcinoma, 
prior antitumor therapy and outcome, menopausal 
status, general medical history, concurrent illness. 
Concomitant  medications, prior use of medication 
containing polysorbate 80 (see Appendix IV) and 
history of allergy; medications and their indication, 
used within one month prior to study entry. 
Physical Exam - including: height and weight, WHO 
index for performance status, vital signs, neurologic 
examination  
 
 
 
Within 7 
days  
prior to 
first infusion 
 
Hematol. * 
 
CBC: RBC, WBC, differential count, platelets count, 
hemoglobin 
Within 7 
days 
prior to  
first infusion 
 
Biochem. * 
Alkaline phosphatase, LDH, AST (SGOT), ALT 
(SGPT), bilirubin, serum creatinine, creatinine 
clearance (if indicated), Na+, K+, calcium, protein, 
albumin, urinalysis (dipstick) 
Within 7 
days 
prior to 
first infusion 
 
 
Radiology 
 
 
• Mammograms 
• Chest-X-Ray (AP and lateral) with or without CT scan 
• Abdominal ultrasound with or without CT scan 
• Bone scan + bone X-rays or CT scan or MRI on hot 
spots observed on bone scan 
• Other instrumental examinations if indicated 
 
Within 2 
months 
prior to 
first infusion 
 
ECG 
 
ECG 
Within 7 
days prior to 
first infusion 
 
 LVEF 
 
MUGA scan or echocardiography  
Within 2 
weeks 
prior to first 
infusion 
 Other 
Investigatio
ns 
 
As clinically indicated 
Within 7 
days prior to 
first infusion 
* Laboratory assessments will be performed whenever possible in the same 
laboratory throughout the study. 
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3.2 Randomization procedure and treatment protocol 
 
Patients were allocated to treatment by an automated minimization 
procedure and stratified by center, number of positive lymph nodes (1–3, 4–9, 
10 or more), ER status (negative, positive, unknown), and menopausal status 
(pre, post). Patients were assigned 1:1 to receive either epirubicin 120 mg/m² 
on day 1, every 21 days for 4 cycles followed by CMF 600/40/600 mg/m² on 
days 1 and 8, every 28 days for 4 cycles (arm A: E→CMF) or the same 
treatment with docetaxel 100 mg/m² on day 1, every 21 days for 4 cycles 
administered after the 4 cycles of epirubicin and before the 4 cycles of CMF 
(arm B: E→T→CMF). Therefore, patients in arm A were assigned to receive 8 
cycles of chemotherapy, while patients in arm B were assigned to receive 12 
cycles. Randomization was done centrally by fax at the coordinating center 
(University of  Naples Federico II, Naples, Italy). 
A third arm initially enrolled patients with four or more positive nodes at 
selected centers to test the feasibility and efficacy of a dose-dense regimen of 4 
cycles of epirubicin 120 mg/m², day 1, every 14 days followed by 4 cycles of 
dose-dense docetaxel 100 mg/m², day 1, every 14 days and then 3 cycles of 
high-dose cyclophosphamide 3000 mg/m², day 1, every 21 days (arm C: 
Edd→Tdd→Chd). A feasibility analysis was planned after inclusion of the first 
25 patients in arm C using pre-specified safety criteria. This analysis led to 
early closure of this dose-intensified arm due to unacceptable toxicity. 
Docetaxel was infused over 1-hour with routine steroid premedication to 
prevent hypersensitivity reactions and fluid retention starting 12 hours before 
and ending 18 hours after the infusion. Antiemetics (5-HT3 receptor 
antagonists) were routinely prescribed before each cycle. Primary prophylaxis 
with granulocyte colony-stimulating factors (G-CSF) was mandatory for arm 
C, whereas it was prohibited for arms A and B. In the event of an absolute 
neutrophil count less than 1.5 x 109/L or platelet count less than 100 x 109/L on 
day 1 of each cycle, treatment was delayed until recovery. Prophylactic G-CSF 
was recommended for subsequent cycles in case of treatment delay due to 
neutropenia lasting more than 7 days or if the patient had suffered febrile 
neutropenia or grade 3-4 infection. If these problems persisted despite G-CSF 
treatment, a 25% dose-reduction was required for further chemotherapy. The 
same dose-reduction was required in case of a delay of more than 7 days due to 
thrombocytopenia, and in case of severe nonhematologic toxicity. If on day 8 
of the CMF cycle, absolute neutrophil count was < 1.0 x 109/L and/or platelets 
were <100 x 109/L, chemotherapy was omitted and the subsequent cycle was 
started on day 21 instead of day 28. 
Radiation therapy was mandatory after breast-conserving surgery and was 
started after completion of chemotherapy. No specific recommendations were 
given for post-mastectomy radiation therapy, which was according to the 
guidelines of each center. Tamoxifen 20 mg/day for 5 years was recommended 
after completion of chemotherapy for premenopausal patients with ER-positive 
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and unknown tumors and to all postmenopausal patients irrespective of ER 
status, according to current practice at the time the protocol was developed.  
 
 
3.3 Statistical considerations 
3.3.1  End-points 
As planned in the protocol primary endpoint was Disease Free Survival 
(DFS) defined as the time between the date of randomization and the date of 
local or distant recurrence or contralateral breast cancer or second primary 
malignancy or death from any cause, whichever occurred first. No 
specification was given in the protocol as to whether consider ductal carcinoma 
in situ (DCIS), either contralateral or ipsilateral, as an event. Quite recently,  
standardized definitions for efficacy endpoints (STEEP system) in adjuvant 
breast cancer trials have been proposed  by a multidisciplinary panel of experts 
with the aim of reducing inconsistencies of results across clinical trials (Hudis 
et al 2007).  
Thus we decided to report the results according to such a system.  
Primary end-point was accordingly re-defined Invasive-DFS (IDFS), which 
excluded DCIS from the events of interest. Efficacy results were also provided 
for Overall Survival (OS), and Recurrence-free survival (RFS). OS was 
defined as the time from randomization to death from any cause. RFS was 
defined as the time between the date of randomization and the date of local or 
distant recurrence or death from any cause, whichever occurred first; thus 
contralaeral breast cancer or second primary (non-breast) cancers were 
excluded (Hudis et al 2007). 
 
3.3.2 Sample size calculation 
The trial was originally designed to enrol 752 patients, 732 for the 
comparison of arm A vs arm B plus 120 patients for the comparison of arm B 
vs arm C. This was based on an expected 5yr DFS equal to 0.55 in arm A 
(Bonadonna et al 1995),  a 10% absolute improvement in arm B and a further 
15% absolute gain in arm C, with a type I error of 0.05 (two sided) and a power 
of 80%. In June 1999 inclusion criteria were amended, allowing the inclusion 
of subjects with 1 to 3 axillary metastases, and sample size was re-estimated 
accordingly leading to a total sample size of 914 patients (794 for the 
comparison of arm A vs arm B plus 120 patients for the comparison of arm B 
vs arm C).  
Upon closure of arm C for toxicity the Steering Committee decided to re-
evaluate again the sample size of the study to possibly increase the power of 
the first comparison. For this final calculation, expected 5yr DFS in arm A was 
set to 0.65 based on the results, which had become available meanwhile, of a 
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previous trial evaluating the efficacy of a block-sequential anthracycline-CMF 
regimen in node-positive patients (De Placido et al 2005).  
Assuming an absolute improvement for the experimental arm (arm B) of 9% 
(HR equal to 0.70), a type I error () equal to 0.05 (two sided) and a power of 
80%, it was estimated that a total of 960 subjects and 250 events would be 
needed for the final analysis.  
All sample size adjustments were done blinded to data. 
 
3.3.3 Statistical analysis 
All efficacy analysis were done on an intention-to-treat basis. All subjects 
receiving at least one treatment dose were considered evaluable for efficacy 
analysis. 
Time-to-event curves were estimated with Kaplan-Meier (K-M) product 
limit, and statistical significance was assessed with a 2-sided log-rank test. 
Adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) were 
estimated using a Cox proportional hazards model that included treatment, 
lymph node metastases (1-3, 4-9, 10+), ER status (negative, positive, 
unknown) and menopausal status (pre/post) as covariates.  
Exploratory subgroup analysis were reported as ‘Forest plot’, with 95% 
confidence intervals, focusing on possible interactions with treatment rather 
than strictly relying on statistical significance. 
All patients who received treatment were considered for toxicity analysis. 
Up to six laboratory exams were planned for each cycle. Statistical analysis of 
toxicity was done in two ways. First, an exact linear permutation test was 
applied to allow for the ordinal nature of toxicity grades (Cytel 7 software, 
Cambridge, MA). Second, an exact chi-square test was applied comparing 
severe (grades 3 to 4) versus non-severe (grades 0 to 2) toxicity. 
Compliance to treatment was reported both on a per patient and a per cycle 
basis, according to treatment actually received. This analysis was descriptive 
only. 
All the analysis were performed with SAS version 8.2 (SAS Inc., Cary, NC, 
USA) and graphs were made with R 2.6.2 (R Foundation for Statistical 
Computing, Vienna, Austria).   
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4   RESULTS AND DISCUSSION 
 
 
4.1 Patients 
 
From July 1998 to July 2002, 998 patients were randomized in to the trial 
(arm A: n=486; arm B: n=486; arm C: n=26). After inclusion of 26 patients in 
arm C, a planned interim safety analysis was conducted to evaluate the 
feasibility of the dose-intensified treatment. All feasibility rules were met 
except for grade 4 skin toxicity in one patient, which led to early closure of 
arm C, for which no further results are reported. Baseline characteristics of all 
randomized patients were well balanced (Table 2). Median age was 51 years 
(range: 23–74). The study included a similar number of pre- and post-
menopausal women. Two-thirds of tumors were ER-positive.  
 
 
 
Table 2: Patient characteristics by treatment arm* 
 
 
E  CMF  
(Total 486) 
No. (%) 
E  T CMF  
(Total 486) 
No. (%) 
 
   
 <50 227 (46.7) 213 (43.8) 
 Age 
 50 259 (53.3) 273 (56.2) 
 Pre 244 (50.2) 243 (50.0) 
 Menopause 
 Post 242 (49.8) 243 (50.0) 
 T1 194 (39.9) 219 (45.1) 
 T2 242 (49.8) 203 (41.8)  TNM 
 T3-4 50 (10.3) 64 (13.2) 
 1-3 179 (36.8) 178 (36.6) 
 4-9 193 (39.7) 198 (40.7)  Nodes (No.) 
 >=10 114 (23.5) 110 (22.6) 
 Ductal 390 (80.3) 378 (77.8) 
 Lobular 59 (12.1) 71 (14.6)  Histology 
 Other 37 (7.6) 37 (7.6) 
 Negative 114 (23.5) 117 (24.1) 
 Positive 319 (65.6) 315 (64.8)  ER 
 Unknown 53 (10.9) 54 (11.1) 
 
* ECMF = epirubicin followed by cyclophosphamide, methotrexate, and 5-
fluorouracil; TNM = tumor, node, metastasis; ER = estrogen receptor 
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4.2 Adherence to treatment 
  
The planned number of chemotherapy cycles was administered to 91% 
patients in arm A and 74% in arm B. Reasons for treatment discontinuation are 
shown in Table 3. Overall, 96% and 93% of patients received four planned 
cycles of epirubicin and CMF, respectively, at a rate that was similar between 
arms, and 83% of patients received 4 cycles of docetaxel.  
Overall, chemotherapy was delayed in 18% of cycles in arm A and 20% of 
cycles in arm B. Dose reduction was applied in 4% of cycles in arm A vs 7% in 
arm B. Docetaxel administration was delayed in 21% of cycles and the dose 
was reduced in 11% of cycles.   
 
 
 
Table3: Reasons for discontinuation of chemotherapy by received treatment* 
 
Reasons E CMF E  T CMF 
Breast cancer relapse 3 7 
Second primary malignancy 0 1 
Adverse experience 17 31 
Consent withdrawal 12 43 
Death 0 1 
Protocol deviation 0 2 
Lost 0 3 
Other 4 25 
Not Reported 10 14 
Total 46   127 
 
* ECMF = epirubicin followed by cyclophosphamide, methotrexate, and 5-
fluorouracil; ETCMF = epirubicin followed by docetaxel followed by 
cyclophosphamide, methotrexate, and 5-fluorouracil 
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4.3 Efficacy 
 
At the date of this analysis (November 30, 2006), 142 patients had died and 
the median follow-up was 62 months. A total of 278 IDFS events had occurred 
(Table 4).  
 
 
 
 
 
 
Table 4: Patients with first IDFS events* 
 
 
E CMF (total 486) 
No. (%) 
E  T CMF  
(total 486) 
No. (%)  
   
 Breast cancer relapse 139 (28.6) 108 (22.2) 
 Loco/regional 25 (5.1) 19 (3.9) 
 Distant 114 (23.5) 89 (18.3) 
 Death 5 (1.0) 7 (1.4) 
 Second primary cancer 5 (1.0) 14 (2.9) 
 Breast 1 (0.2) 3 (0.6) 
 Other 4 (0.8) 11 (2.3) 
 Total IDFS events 149 (30.7) 129 (26.5) 
 None (event-free patients) 337 (69.3) 357 (73.5) 
 
* ECMF = epirubicin followed by cyclophosphamide, methotrexate, and 5-
fluorouracil; ETCMF = epirubicin followed by docetaxel followed by 
cyclophosphamide, methotrexate, and 5-fluorouracil; IDFS = invasive disease 
free survival. 
 
 
 
 
 
 
 
IDFS was better in the experimental arm (B), although the difference did 
not reach statistical significance (log-rank P = 0.134) (Figure 1). The estimated 
probability of being free of any IDFS event at 5 years was 74% for arm B and 
68% for arm A (HR 0.82, 95% CI 0.64-1.03; P = 0.1337).  
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Figure 1: IDFS for arm A and for arm B. ECMF = epirubicin followed by 
cyclophosphamide, methotrexate, and 5-fluorouracil; ETCMF = epirubicin 
followed by docetaxel followed by cyclophosphamide, methotrexate, and 5-
fluorouracil. 
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The estimated probability of being recurrence-free at five years was 
significantly better for arm B than for arm A (76% vs 69%, respectively; HR 
0.75; 95% CI 0.59-0.96; P = 0.0332; Figure 2).  
 
 
 
 
 
Figure 2: RFS for arm A and for arm B. ECMF = epirubicin followed by 
cyclophosphamide, methotrexate, and 5-fluorouracil; ETCMF = epirubicin 
followed by docetaxel followed by cyclophosphamide, methotrexate, and 5-
fluorouracil. 
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A statistically significant  improvement was observed for OS (Figure 3), 
with an estimated probability of being alive at five years of 90% for arm B and 
85% for arm A (HR 0.67; 95% CI 0.48-0.94; P = 0.0168).  
 
 
 
 
 
 
 
 
 
 
 
 
E-CMF 
E-T-CMF 
Log-rank p =  0.0168 
Figure 3: OS for arm A and for arm B. ECMF = epirubicin followed by 
cyclophosphamide, methotrexate, and 5-fluorouracil; ETCMF = epirubicin 
followed by docetaxel followed by cyclophosphamide, methotrexate, and 5-
fluorouracil. 
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Multivariate analysis that included treatment, lymph node metastases, ER 
status and menopausal status as covariates confirmed these results. There was 
no evidence of heterogeneity of treatment efficacy in the subgroups of patients 
stratified according to age, menopausal status, ER status and number of 
positive lymph nodes (Figure 4). 
 
 
 
 
 
Figure 4: Forest Plot of Overall Survival (OS) and Relapse Free Survival (RFS) 
Hazard Ratios of main subgroups (exploratory analysis). 
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4.4 Toxicity 
 
In both arms, grade 3-4 neutropenia rates were higher than usually reported 
(84% and 90% in arms A and B, respectively; P = 0.009). The rate of febrile 
neutropenia was significantly higher in the experimental arm (11.6% vs 6.2%). 
When the analysis of neutropenia was limited to laboratory values recorded the 
day before staring a new cycle (day 21 for epirubicin and docetaxel; day 28 for 
CMF), grade 3-4 neutropenia rates decreased to 10% and 12% for arm A and 
arm B, respectively (P = 0.42). Severe anemia and thrombocytopenia were 
uncommon (Table 5).  
 
 
 
Table 5: Hematological toxicity: grade 3-4 events according to treatment arm* 
 
 ECMF  
No. (%) 
ETCMF 
No. (%)  
P† 
Neutropenia at 
nadir 
406 (84.4) 434 (90.2) 0.0087 
Neutropenia at 
recycling 
50 (10.4) 59 (12.4) 0.4158 
Anemia 10 (2.1) 12 (2.5) 0.6739 
Thrombocytopenia 11 (2.3) 11 (2.3) 0.9999 
Leucopenia 244 (50.6) 315 (65.5) <0.0001 
Febrile neutropenia 30 (6.2) 56 (11.6) 0.0032 
 
*ECMF = epirubicin followed by cyclophosphamide, methotrexate, and 5-
fluorouracil; ETCMF = epirubicin followed by docetaxel followed by 
cyclophosphamide, methotrexate, and 5-fluorouracil; 
 
†Fisher’s exact test comparing grade 0-1-2 vs 3-4 
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Grade 3–4 nonhematologic adverse events are reported in Table 6. More 
patients in arm B experienced at least one nonhematologic event. Several 
events were reported only for arm B: neurotoxicity in 1% of patients; 
hypersensitivity in 1.6% of patients; and peripheral edema in <1% or patients. 
Other grade 3–4 toxicities that were more frequent among docetaxel patients 
included: asthenia, arthralga, myalgia (none in control arm), diarrhea, 
stomatitis, and skin and nail disorders (none in control arm). Cardiac function 
toxicity occurred in only in arm B (1 patient; 0.2%), whereas cardiac ischemia 
occurred only in arm A (1 patient; 0.2%). 
Overall, 5 non-breast cancers were reported in arm A: small-cell lung 
(n=1), thyroid (n=1), pancreatic (n=1), ovarian (n=1), and unspecified uterine 
(n=1). Twelve non-breast cancers occurred in arm B: colon (n=2), thyroid 
(n=2), melanoma (n=1), kidney (n=1), tonsil (n=1), PNET (n=1), ovarian 
(n=1), endometrial (n=1), 1 uterine cervix (n=1), and 1 unknown (n=1). 
Neither acute myeloid leukemia nor myelodysplastic syndrome has been 
recorded to date.  
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Table 6: Nonhematological toxicity (grade 3-4 events) according to treatment 
arm*  
 
  
E  CMF 
No. (%) 
E  T CMF 
No. (%) P† 
Allergy 0 (0.0) 8 (1.6) 0.0037 
Arthralgy 1 (0.2) 6 (1.2) 0.0689 
Asthenia 12 (2.5) 31 (6.4) 0.0029 
Cardiac arrhythmias 0 (0.0) 0 (0.0) 0.9999 
Cardiac function 0 (0.0) 1 (0.2) 0.499 
Cardiac ischemia 1 (0.2) 0 (0.0) 0.9999 
Cardiac pericardial 0 (0.0) 0 (0.0) 0.9999 
Diarrhea 5 (1.0) 22 (4.5) <0.0001 
Local toxicity 2 (0.4) 3 (0.6) 0.6862 
Myalgia 0 (0.0) 7 (1.5) 0.0075 
Nail disorders 0 (0.0) 8 (1.7) 0.0037 
Nausea 23 (4.7) 34 (7.0) 0.1353 
Neuromotor 0 (0.0) 5 (1.0) 0.0306 
Neurosensory 0 (0.0) 5 (1.0) 0.0306 
Pain 0 (0.0) 4 (0.8) 0.0616 
Peripheral edema 0 (0.0) 3 (0.6) 0.1238 
Pulmonary 2 (0.4) 2 (0.4) 0.9999 
Skin 0 (0.0) 15 (3.1) <0.0001 
Stomatitis 30 (6.2) 46 (9.5) 0.0565 
Vomiting 25 (5.2) 35 (7.2) 0.1851 
Weight gain 1 (0.2) 1 (0.2) 0.9999 
 
*ECMF = epirubicin followed by cyclophosphamide, methotrexate, and 5-
fluorouracil; ETCMF = epirubicin followed by docetaxel followed by 
cyclophosphamide, methotrexate, and 5-fluorouracil; 
 
†Fisher’s exact test comparing grade 0-1-2 vs 3-4 
 33 
4.5 Discussion 
 
The TAXIT 216 trial shows that the addition of four cycles of docetaxel to a 
block-sequential epirubicin-CMF regimen reduces the risk of recurrence and 
death in patients with lymph-node positive ESBC. 
Although the reduction in risk recurrence did not reach statistical 
significance for IDFS (the primary end point), it was statistically significant for 
RFS. This apparent discrepancy is probably due to the inclusion of non-breast 
second primary tumors among the events used to estimate IDFS as required by 
STEEP guidelines (Hudis et al 2007). Although inclusion of non-breast cancer 
events in the analysis of IDFS avoids misdiagnosis of a distant recurrence as a 
second primary cancer, it dilutes any treatment effect and so, these second 
primaries, should not be related to the treatment under study.  
In our trial, there was a small, not statistically significant, excess of non-
breast second primary tumors in the experimental arm. However, no evidence 
of excess non-breast cancer events in taxane-based arms emerged from any of  
the randomized trials of taxane-based adjuvant regimens published to date. 
Furthermore,  the incidence of non-breast primaries in our experimental arm is 
around the average of other trials, whereas incidence was very low in our 
control arm (Table 7). These observations suggest that the imbalance of non-
breast cancer events in the TAXIT 216 trial is probably unrelated to treatment 
and occurred by chance. 
Consequently, their inclusion in the analysis of the primary end point may 
have weakened the power of the comparison. In this situation, a better estimate 
of the therapeutic effect may be RFS, which in our trial was significantly 
improved by the addition of docetaxel (25% relative risk reduction; P = .0332). 
Consistent with this outcome, there was also a statistically significant 
advantage in OS (33% relative risk reduction; P = .0168) in the experimental 
arm.  
Several phase III randomized trials have evaluated the effect of taxanes, 
combined or in sequence with anthracycline-based regimens, in the adjuvant 
treatment of ESBC patients. Most, but not all, the efficacy data available show 
a significant reduction of the risk of recurrence for the taxane-based treatment 
versus the control anthracycline-based regimen (Budzar et al 2002, Martin et al 
2005, Mamounas et al 2005, Evans et al 2005, Gianni et al 2005, Jones et al 
2006, Bear et al 2006, Martin et al 2008, Francis et al 2008, Goldestein et al 
2008). On the other hand, a benefit in OS has been found only in a few trials 
(Henderson et al 2003, Fountzilas et al 2005, Martin et al 2005, Roche et al 
2006). However, a recent meta-analysis of all available randomized trials 
suggests that, on average, the addition of a taxane to anthracycline-based 
treatment yields significant benefits in terms of OS (De Laurentiis et al 2008). 
The final analysis of our trial is consistent with this finding, and lends support 
to the use of taxanes, particularly docetaxel, in the adjuvant setting. 
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Table 7: Non-breast primaries in published adjuvant taxane trials  
 
 
Non-Breast Cancers reported as first event 
 
Taxane 
No. (%) 
No Taxane 
No. (%) 
Paclitaxel-based Trials 
 
  
M.D.ANDERSON 
(MDACC2002) NR NR 
CALGB 9344 NR NR 
GEICAM 9906 15 (2.4) 12 (1.9) 
HeCOG 10/97 3 (1.0)* 4 (1.3)* 
NSABP B28 36 (2.1) 50  (2.9) 
Docetaxel-based Trials 
 
  
BCIRG 001 13 (1.7) 18 (2.4) 
NSABP B27 43  (2.7) 17 (2.1) 
Anglo-Celtic NR NR 
BIG 2-98 32 (1.7) 18 (1.9) 
PACS 01 17 (1.7)* 25  (2.5)* 
ECOG E 2197 57 (3.9)* 39 (2.6)* 
USON NR NR 
Taxit 216 11 (2.3) 4 (0.8) 
 
 
 
* Events not used to estimate primary end-point; NR: not reported 
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Various anthracycline-based regimens have been used as control in adjuvant 
taxane trials. However, there is some controversy as to whether the 
anthracyline-based control arms in such trials could be considered standard. 
Indeed, not all anthracycline-based regimens used as control arms in such trials 
have clearly proven superiority versus CMF, thus confounding the 
interpretation of results.  
In such a situation, clinical preference should be given to taxane-based 
regimens that have been compared to an anthracycline-based control. The 
block-sequential E–CMF regimen used as control arm in the TAXIT 216 trial 
is among the few control regimens in adjuvant taxane trials, if not the only one, 
that has bested CMF in direct randomized comparisons (De Placido et al 2005, 
Poole et al 2006). A similar block-sequential regimen, but with a lower number 
of cycles, was the control arm in the recently published BIG2-98 trial (Francis 
et al 2008), has yielded comparable results.  
A crucial issue is whether taxanes should be combined with anthracyclines 
or whether they should be administered sequentially after an anthracycline-
based regimen. Both options have theoretical advantages and drawbacks: 
combination regimens may require dose reductions for both compounds but, in 
theory, can exploit drug synergism; on the other hand, in sequential regimens 
both compounds can be administered at optimal doses.  
Three decades ago, Norton and Simon reported that the growth of solid 
tumors could be described by Gompertzian kinetics, in which the rate of 
regrowth of a tumor increases as the tumor shrinks in response to therapy. The 
Norton–Simon hypothesis predicts that this resistance might be overcome by 
switching from initial chemotherapy agents to newer agents at the maximally 
tolerated dose. The results of the TAXIT 216 trial are consistent with this 
hypothesis.  
However, similar results have been obtained with regimens in which the 
taxane was given in combination with the anthracycline. De Laurentiis and 
colleagues, in their meta-analysis of randomized trials (De Laurentiis et al 
2008), made an exploratory indirect comparison between block-sequential and 
combination regimens and did not find a statistically significant difference in 
efficacy. However, because of the indirect nature of this comparison, we 
cannot exclude that there could be moderate but meaningful differences in 
efficacy between sequential and combination regimens. The only trial reporting 
a direct randomized comparison between a sequential and combination taxane-
based regimen is the BIG2-98 trial, which showed an advantage for the 
sequential regimen of borderline statistical significance. 
However, caution should be exerted in drawing conclusions about this issue 
based on the BIG2-98 and TAXIT 216 trials because of design issues (ie, the 
longer treatment duration of the experimental arm, the different 
docetaxel/anthracycline doses, the unplanned nature of this comparison). 
Results of other adjuvant trials, such as BCIRG 005 and NSABP B-30, 
comparing sequential and concurrent anthracycline-docetaxel regimens, are 
eagerly awaited.  
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There is some controversy about whether taxanes produce consistent benefit 
across specific subgroups of patients. Data from individual trials suggest that 
the benefits of taxanes may be lower, if not negligible, for patients with 4 or 
more positive nodes or ER-positive tumors. Other trials suggest that the benefit 
differs between younger and older patients.  
In our trial, docetaxel reduced the risk of recurrence irrespective of ER 
status (positive vs negative), nodal status (1-3 vs  4-9 vs 10+), age (50 vs >50 
years) and menopausal status (pre vs  post). Although the relative benefit varies 
across some subgroups of patients (Figure 4), there is no statistically 
significant heterogeneity indicating that this arose by chance. Therefore, our 
study indicates that  the number of positive lymph nodes, age, menopausal 
status and ER status should not be used in clinical practice to identify patients 
who may (or may not) benefit from our experimental regimen. The same 
conclusion emerges from a recent meta-analysis of randomized trials. 
Two limitations of our trials deserve discussion. First, compared with 
similar trials, TAXIT 216 has a smaller than average sample size. It may be 
argued that this decreases the value of the trial results. However, underpowered 
trials have by definition a high chance of not detecting a statistically significant 
difference between treatments (ie, a high chance of being false-negative). 
Conversely, once a statistically significant difference is detected, as in the case 
of our trial, the small sample size does not decrease the absolute strength of 
such evidence, although it affects the precision of the point estimate for the 
HR. Second, our experimental treatment lasted longer than other taxane-based 
regimens and this may raise concerns of excess toxicity and discomfort for 
patients.  
In this regard, our toxicity profile appears reassuring. Hematologic severe 
adverse events were rare in our experimental arm except for grade 3-4 
neutropenia.  
The high incidence of neutropenia was probably due to large number of 
laboratory examinations (up to six) that were required by the protocol for each 
cycle of chemotherapy thereby increasing the change of recording the 
neutropenic nadir. 
In fact, when we limited the analysis of adverse events to the day planned 
for chemotherapy administration, the rate of severe neutropenia was similar to 
that of the control arm and was lower to that generally reported for shorter-
lasting taxanes-based regimens.  
Febrile neutropenia affected more patients in the experimental arm than in 
the control arm (11.6% vs 6.2%), but its frequency was similar to that reported 
for shorter block-sequential regimens (Roche et al 2006, Martin et al 2008) and 
less than the 25% reported for the docetaxel, doxorubicin cyclophosphamide 
(TAC) regimen (Martin et al 2005).  
Among the other taxane-specific adverse events, severe neurotoxicity was 
rare (1%) and less frequent than in shorter paclitaxel-based regimens (Martin et 
al 2008, Mamounas et al 2005, Henderson et al 2003, Citron et al 2003, 
Sparano et al 2008).  
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Furthermore, recent data indicate that for patients, the duration of an 
adjuvant regimen is less important than expected and most are willing to accept 
a longer-lasting treatment if it is associated with a marginal additional benefit 
(Duric et al 2008). 
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5 CONCLUSIONS 
 
Adjuvant chemotherapy, significantly, decreases the risk of recurrence and 
death in women with node-positive operable breast cancer. CMF regimens first 
and anthracycline-based combinations later, became the standard treatment for 
operable breast cancer. 
In the 1990s, the taxanes, docetaxel and paclitaxel, were incorporated to the 
standard armamentarium for metastatic breast cancer. The taxanes are partially 
non cross-resistent with anthracyclines and, therefore, several regimens using 
taxanes and anthracyclines (either in combination or in sequence) were tested 
in the adjuvant setting. 
In this context, the TAXIT 216 trial was designed to assess the efficacy of 
adding docetaxel in a sequential anthracycline-based regimen; with a median 
follow-up of 62 months, our study is the only one to show an overall survival 
benefit compared with an adeguate anthracycline regimen. 
In conclusion, our data suggest that including docetaxel  into a block-
sequential epirubicin-CMF regimen significantly reduces the risk of relapse 
and death for node positive early stage breast cancer.  
 This benefit is independent of age, menopausal status, ER status and nodal 
status. This advantage comes at the cost of an increased, but, acceptable, 
toxicity. 
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ABSTRACT 
 
 
Background: Docetaxel is among the most active drugs for breast cancer. This 
trial was aimed at comparing the efficacy and tolerability of a block-sequential 
chemotherapy regimen containing docetaxel to a standard anthracycline-based 
regimen as adjuvant therapy in node-positive (N+) early breast cancer. 
Methods: Between July 1998 and July 2002, 972 N+ early breast cancer patients 
were randomized to either arm A (ECMF): Epirubicin (E) 120 mg/m2 iv d1 q21 
x 4 cycles followed by Cyclophosphamide 600 mg/m2 iv, Methotrexate 40 mg/m2 
iv and Fluorouracil 600 mg/m2 iv (CMF) dd1,8 q28 x 4 cycles or arm B 
(ETCMF) in which Docetaxel 100 mg/ m2 iv (T) d1 q21 x 4 cycles was 
administered after the 4th cycle of E and before the 1st cycle of CMF. Treatment 
allocation was performed by a computer program using a minimization algorithm. 
Stratification factors were: center, lymph node involvement (1 to 3, 4 to 9, > 10), 
estrogen receptor status (negative/positive/unknown), menopausal status 
(pre/post). The study was designed to detect a hazard ratio of 0.70, assuming an  
of 0.05 (two-sided), a power of 0.80 and an expected DFS in Arm A of 0.65 at 5 
years. This required 480 pts per Arm and 250 events. Final results are reported 
according to the standardized system for efficacy end-points (STEEP system). 
Results: As of November 30th 2007, 486 pts were enrolled in arm A and 486 in 
arm B, 278 primary events were recorded and the median follow up was 62 
months. Invasive disease-free survival (IDFS) at 5 years was 74% in arm B vs 
68% in arm A (p=0.13) with an estimated adjusted Hazard Ratio (HR) of 0.82 
(95%CI: 0.64-1.03). Recurrence-free survival (RFS), whose estimate does not take 
into account second primaries, was significantly better for arm B than for the arm 
A (76% vs 69%, p = 0.0332 with a HR of 0.75 (0.59-0.96).  A statistically 
significant improvement was also observed for overall survival (OS). With a total 
of 142 deaths recorded, estimated OS at five years was equal to 90% for arm B 
and 85% for arm A (p=0.0168; HR=0.67, 95%CI: 0.48-0.94).  
Conclusions: The block-sequential ETCMF regimen yields a significant 
improvement of RFS and OS as compared to ECMF. 
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INTRODUCTION 
 
Adjuvant chemotherapy is able to reduce the risk of recurrence and death of 
radically-resected early breast cancer (EBC) and anthracycline-based 
combinations have been shown on average to be superior to older combinations, 
like CMF (cyclophosphamide-methotrexate-fluorouracil) (1). The Taxit 216 trial 
was designed by Italian investigators in 1998 in the attempt to improve the 
efficacy of a standard adjuvant chemotherapy for node-positive early breast 
cancer. At that time, the pivotal role of anthracycline-based chemotherapy had just 
been established by the overview analysis of all randomized trials conducted by 
the Early Breast Cancer Trialists’ Collaborative Group (2). Compared with the 
combination of cyclophosphamide, methotrexate, and fluorouracil (CMF), 
anthracycline-based regimens appeared to reduce on average the annual breast 
cancer death rate by approximately 12%. These findings encouraged the diffusion 
of anthracycline-based regimens and, in the absence of direct comparison among 
various anthracycline-based schedules, different regimens were adopted as 
standard treatment worldwide based on local preference and attitude.  
In this scenario, a sequential regimen consisting of 4 courses of doxorubicin 
followed by various courses of CMF gained widespread acceptance in Europe. 
This was fuelled by the results of a randomized trial by Bonadonna et al. (3, 4) in 
which this block-sequential regimen compared favorably with a regimen 
alternating doxorubicin and CMF courses. This observation was also consistent 
with mathematical models that predicted better outcomes with block-sequential 
therapy than with an alternating regimen of non–cross-resistant agents (5). 
Therefore, despite the lack of trials directly comparing the block-sequential 
therapy with the classical CMF regimen, this regimen was regarded as a standard 
treatment by many clinicians in Europe and was, thus, chosen as standard 
reference arm by the Taxit 216 investigators. Nonetheless, the superiority of the 
block-sequential regimen over classical CMF has been more recently 
demonstrated for both anthracycline compounds, doxorubicin (6) and epirubicin 
(7), thus providing further support to the reference arm in our trial.  
Taxanes were introduced for treatment of advanced breast cancer in the 1990s 
and their potential utility as adjuvant therapy was well acknowledged in 1998. 
Docetaxel, in particular appeared to be a highly effective compound as 
monochemotherapy in the treatment of metastatic breast cancer and its activity in 
anthracycline-resistant disease was well defined. Phase II studies showed a 
response rate ranging from 48.2% in anthracycline resistant patients to 38.8% in 
anthracycline refractory patients (8, 9). These data were confirmed  by the phase 
III study conducted in anthracycline failure patients in which docetaxel was 
compared to the combination Mitomycin C vinblastine (10). 
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In the TAXIT 216 trial we aimed to assess the efficacy of adding docetaxel in a 
block-sequential fashion to a regimen with doxorubicin followed by CMF. In 
accordance with the Norton-Simon model (5), this regimen should warrant the 
highest dose-intensity for each drug used at standard dose while theoretically 
limiting the increase of toxicity, thus possibly yielding the best chance of tumor 
eradication.  
 5 
METHODS 
 
Study Population 
 
Women first eligible for the study were between 18 and 64 years old and had 
undergone primary surgery with clear margins (ie, modified mastectomy or 
tumorectomy) plus axillary dissection for unilateral operable carcinoma of the 
breast (stage II-IIIa). Randomization was required within 6 weeks since breast 
cancer surgery. 
In the original protocol, women were eligible if they had histologically proven 
tumor involvement in at least 4 axillary lymph-nodes (out of a minimum of 10 
nodes removed). The trial was amended one year later to allow inclusion of 
patients with 1-3 axillary metastases and until 70 years old. Other main eligibility 
criteria included: baseline left ventricular ejection fraction (LVEF), as measured 
by echocardiography or MUGA scan, above the lower normal limit of each 
participating institution; adequate hematologic (granulocyte count  2x109/L, 
platelet count  100x109/L), hepatic (transaminases  1.5 x the upper limit of 
normal [ULN], alkaline phosphatases  2.5 x ULN, and bilirubin  ULN) and 
renal (serum creatinine  140 µmol/L [1.6 mg/DL] or creatinine clearance  60 
ml/min) function. Major exclusion criteria included pregnancy, documented 
history of cardiac disease contraindicating anthracyclines, previous cancer (except 
treated basal cell and squamous cell carcinoma of the skin or cancer of the uterine 
cervix), previous radiation therapy, hormone therapy, or chemotherapy for breast 
cancer, peripheral neuropathy > grade 2 according to the NCI Common Toxicity 
Criteria v2.0. Potentially eligible patients underwent staging by bone scan, chest x-
ray, abdominal ultrasound, and contralateral mammography. Estrogen receptor 
(ER) status (positive vs negative) was evaluated by immunohistochemistry with a 
cut-off of 10% of cells with specific staining. Written informed consent was 
obtained before randomization. The protocol was reviewed and approved by the 
ethics committee/institutional review board and the study was conducted 
according to the Declaration of Helsinki and European Good Clinical Practice 
requirements.  
 
Randomization procedure and Treatments 
 
This study was an open-label, multicenter, randomized trial. Patients were 
randomized to the treatment groups through an automated minimization 
procedure that used center, lymph node metastases (1-3, 4-9, 10+), ER status 
(negative, positive, unknown) and menopausal status (pre/post) as stratification 
factors. Randomization was done centrally by fax at the coordinating center 
(University Federico II, Napoli, Italy). 
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Patients were assigned in a 1:1 ratio to receive epirubicin 120 mg/m² on day 1 
every 21 days for 4 cycles followed by CMF 600/40/600 mg/m² on day 1,8 every 
28 days for 4 cycles (arm A: E→CMF) or the same treatment with the addition of 
docetaxel 100 mg/m² on day 1 every 21 days for 4 cycles in between the 4 cycles 
of epirubicin and the 4 cycles of CMF (arm B: E→D→CMF). Therefore, patients 
in arm A were assigned to receive a total of 8 cycles of chemotherapy, while 
patients in arm B were assigned to receive a total of 12 cycles of chemotherapy. 
A third arm was initially open only for N>4+ patients at some selected centers to 
test feasibility and efficacy of a dose-intensified regimen, which included 4 
cycles of dose-dense epirubicin (120mg/m² d1 q14) followed by 4 cycles of dose-
dense docetaxel (100mg/m² d1 q14) and then 3 cycles of high-dose 
cyclophosphamide (3000 mg/m² d1 q21) (arm C: Edd→Ddd→Chd). A feasibility 
analysis was planned after inclusion of the first 25 patients on arm C using pre-
specified safety criteria. This analysis led to early closure of this dose-intensified 
arm. Irrespective of arm, chemotherapy was delivered on an outpatient basis: 
docetaxel was infused over 1-hour period with routine steroid premedication, to 
prevent docetaxel-related hypersensitivity or fluid retention, starting 12 hours 
before and ending 18 hours after the docetaxel infusion. Antiemetics (5-HT3 
receptor antagonists) were prescribed routinely before each cycle. Primary 
prophylaxis with granulocyte colony-stimulating factors (G-CSF), but not with 
antibiotics, was mandatory for arm C, while it was prohibited for arm A and arm 
B. In the event of an absolute neutrophil count (ANC) less than 1.5 x 109/L or a 
platelet count less than 100 x 109/L on day 1 of each cycle, treatment was delayed 
until recovery. Prophylactic G-CSF was recommended for subsequent cycles in 
case of a treatment delay due to neutropenia of more than 7 days or if the patient 
had suffered febrile neutropenia or grade 3-4 infection. If despite G-CSF 
treatment these problems persisted, a 25% dose-reduction was required for 
further chemotherapy administrations. The same dose-reduction was required in 
case of >7 days delay due to piastrinopenia and generally if a severe non-
hematologic toxicity developed. If on day 8 of the CMF cycle, ANC was < 1.0 x 
109/L and/or platelets were <100 x 109/L, chemotherapy was omitted and the 
subsequent cycle was started on day 21 instead of day 28. 
Radiation therapy was mandatory after breast-conserving surgery and was 
delivered after completion of chemotherapy. No specific recommendations were 
given for post-mastectomy radiation therapy, which was delivered according to 
the guidelines of each center.  
Tamoxifen therapy at 20mg/day for 5 years therapy was recommended after 
completion of chemotherapy to pre-menopausal patients with ER-positive tumors 
and to all post-menopausal patients irrespective of ER status, according to current 
practice at the time the protocol was developed.  
 
 7 
Statistical Considerations 
 
End-Points 
 
As planned in the protocol, primary endpoint was Disease Free Survival (DFS) 
defined as the time between the date of randomization and the date of local or 
distant recurrence or contralateral breast cancer or second primary malignancy or 
death from any cause, whichever occurred first. No specification was given in the 
protocol as to whether consider ductal carcinoma in situ (DCIS), either 
contralateral or ipsilateral, as an event.  
Quite recently,  standardized definitions for efficacy endpoints (STEEP 
system) in adjuvant breast cancer trials have been proposed  by a multidisciplinary 
panel of experts with the aim of reducing inconsistencies of results across clinical 
trials (11). Thus we decided to report the results according to such a system. 
Primary end-point was accordingly re-defined Invasive-DFS (IDFS), which 
excluded DCIS from the events of interest (11).  
Efficacy results were also provided for Overall Survival (OS), and Recurrence-
free survival (RFS) (11). OS was defined as the time from randomization to death 
from any cause. RFS was defined as the time between the date of randomization 
and the date of local or distant recurrence or death from any cause, whichever 
occurred first; thus contralateral breast cancer or second primary (non-breast) 
cancers were excluded (11). 
 
Sample size calculation 
 
The trial was originally designed to enrol 752 patients, 732 for the comparison 
of arm A vs arm B plus 120 patients for the comparison of arm B vs arm C. This 
was based on an expected 5yr DFS equal to 0.55 in arm A (3),  a 10% absolute 
improvement in arm B and a further 15% absolute gain in arm C, with a type I 
error of 0.05 (two sided) and a power of 80%. In June 1999 inclusion criteria were 
amended, allowing the inclusion of subjects with 1 to 3 axillary metastases, and 
sample size was re-estimated accordingly, leading to a total sample size of 914 
patients (794 for the comparison of arm A vs arm B plus 120 patients for the 
comparison of arm B vs arm C). Upon closure of arm C for toxicity the Steering 
Committee decided to re-evaluate again the sample size of the study to possibly 
increase the power of the first comparison. For this final calculation, expected 5yr 
DFS in arm A was set to 0.65 based on the results, which had become available 
meanwhile, of a previous trial evaluating the efficacy of a block-sequential 
anthracycline->CMF regimen in node-positive patients (6). Assuming an absolute 
improvement for the experimental arm (arm B) of 9% (HR equal to 0.70), a type I 
error () equal to 0.05 (two sided) and a power of 80%, it was estimated that a 
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total of 960 subjects and 250 events would be needed for the final analysis. All 
sample size adjustments were done blinded to data. 
 
Statistical analysis 
 
All efficacy analysis were done on an intention-to-treat basis. All subjects 
receiving at least one treatment dose were considered evaluable for efficacy 
analysis. Time-to-event curves were estimated with Kaplan-Meier (K-M) product 
limit, and statistical significance was assessed with a 2-sided log-rank test. 
Adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) were 
estimated using a Cox proportional hazards model that included treatment, lymph 
node metastases (1-3, 4-9, 10+), ER status (negative, positive, unknown) and 
menopausal status (pre/post) as covariates.  
Exploratory subgroup analysis were reported as ‘Forest plot’, with 95% 
confidence intervals, focusing on possible interactions with treatment rather than 
strictly relying on statistical significance. 
All patients who received treatment were considered for toxicity analysis. Up to 
six laboratory exams were planned for each cycle. Statistical analysis of toxicity 
was done in two ways. First, an exact linear permutation test was applied to allow 
for the ordinal nature of toxicity grades (Cytel 7 software). Second, an exact chi-
square test was applied comparing severe (grades 3 to 4) versus non-severe (grades 
0 to 2) toxicity. 
Compliance to treatment was reported both on a per patient and a per cycle 
basis, according to treatment actually received. This analysis was descriptive only. 
All the analysis were performed with SAS version 8.2 (SAS Inc., Cary, NC, USA) 
and graphs were made with R 2.6.2 (R Foundation for Statistical Computing, 
Vienna, Austria).   
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RESULTS 
 
 
Patients characteristics 
 
From July 1998 to July 2002, 998 patients were randomized in to the trial (arm 
A: n = 486; arm B: n = 486; arm C: n = 26).  
After inclusion of 26 patients in arm C, a planned interim safety analysis was 
conducted to evaluate the feasibility of this dose-intensified treatment according to 
the planned feasibility rules. At this analysis, all rules were met except for the 
development of a grade 4 skin toxicity in one patient, which led to early closure of 
the arm. Therefore, no further results are reported for the arm C.  
Baseline characteristics of patients in the arms A and B are reported in table 1. 
Baseline characteristics of all randomized patients were well balanced across the 
two treatment groups. Median age of patients was 51 years (range 23-74). The 
study included an equal number of pre- and post-menopausal women. Two thirds 
of patients were ER-positive.  
 
 
Adherence to Treatment  
 
The planned number of chemotherapy cycles was delivered to 91% patients in 
arm A and 74% in arm B. Reasons for treatment discontinuation are reported in 
table 2. Once separate drugs are considered, the planned number of four cycles 
was achieved in 96%, 83% and 93% of patients for epirubicine, docetaxel and 
CMF, respectively, without difference between arms.  
Chemotherapy administration was delayed in 18% of cycles for arm A and 
20% of cycles in arm B. A dose reduction was applied in about 4% of cycles in 
arm A vs 7% in arm B. With specific regard to docetaxel administration, a delay 
occurred in 21% of cycles and the dose was reduced in approximately 11% of 
cycles.   
 
 
Efficacy  
 
At the end date of November 30th 2006, 142 patients had died and median 
follow up of alive patients was equal to 62 months. According to the primary 
endpoint (IDFS) 278 events had occurred and their distribution between treatment 
arms is reported in table 3. 
The experimental arm improved IDFS, although the difference did not reach 
statistical significance (log-rank p-value = 0.134). The estimated probability of 
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being free of any IDFS event at 5 years was equal to 0.74 for experimental arm 
and 0.68 for control arm. A statistically significant improvement was conversely 
observed for OS. Estimated probability of being alive at five years was equal to 
0.90 for experimental arm and 0.85 for control arm (log-rank p-value = 0.0168). 
RFS curves, whose estimate do not take into account breast and non-breast second 
primaries. Estimated probability of being recurrence-free at five years was 
significantly better for the experimental arm than for the control arm (0.76 vs 0.69, 
respectively: log-rank p-value = 0.0332).  
Multivariable analysis that included treatment, lymph node metastases, ER 
status and menopausal status as covariates confirmed these results. Hazard ratios 
and 95% confidence intervals for the three efficacy endpoints are reported in table 
4. An exploratory analysis was carried out according to patient age, menopausal 
status, ER status and lymph node status to check whether these factors could 
modify the relative efficacy of the experimental arm as compared to the control 
arm. There was no evidence of heterogeneity of treatment efficacy in the various 
subgroups of patients. 
 
 
Toxicity  
 
Febrile neutropenia was significantly more frequent for patients in the 
experimental arm (11.6% vs 6.2%). Observed grade 3-4 neutropenia rates were 
much higher than commonly reported in both arms (84% vs 90% of subjects in 
arm A and arm B, respectively) and differed significantly (p=0.009). This very 
high incidence of neutropenia may possibly be due to the many laboratory exams 
(up to six) that were requested by the protocol for each chemotherapy cycle, thus 
yielding a high chance of registering the neutropenic nadir. Indeed, when the 
analysis was limited to laboratory values registered approximately at the time 
planned for recycling (day 21 for epirubicine and docetaxel; day 28 for CMF) 
grade 3-4 neutropenia rates dropped down to 10% vs 12% for arm A vs arm B, 
respectively and the difference was no more statistically significant (Fisher’s exact 
test: p=0.42). Severe anemia and thrombocytopenia were uncommon.  
More patients in arm B experienced at least one severe adverse event. Severe 
allergic reactions were rare (1.6% of patients) but they occurred only in the 
experimental arm. Peripheral edema was more frequent in the docetaxel arm but it 
was severe only in 3 patients (0.6%). Neurotoxicity was also more frequently 
reported for patients in arm B, but was only occasionally of grade 3 (1%). Other 
severe toxicities that were more frequent among docetaxel patients included: 
asthenia, arthralgy, myalgia,  diarrhea, stomatitis, skin and nail disorders. 
Overall, 5 non-breast cancers were recorded in arm A, including 1 small cell lung 
cancer, 1 thyroid cancer, 1 pancreatic carcinoma, 1 ovary carcinoma and 1 
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unspecified uterine cancer. Twelve non-breast cancers were observed in arm B: 2 
colon cancers, 2 thyroid cancers, 1 melanoma, 1 kidney carcinoma, 1 tonsil cancer, 
1 PNET, 1 ovarian cancer, 1 endometrial cancer, 1 cancer of the uterine cervix and 
1 unknown cancer. No acute myeloid leukaemia or myelodisplastic syndrome have 
been recorded to date. 
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DISCUSSION 
 
The Taxit 216 trial demonstrates that the introduction of four cycles of 
docetaxel into a block-sequential epirubicin-CMF regimen reduces the risk both of 
recurrence and of death of node-positive EBC patients. The effect on the risk of 
recurrence does not reach statistical significance when the analysis concerns the 
primary end-point of the study, i.e the IDFS. However, it emerges as statistically 
significant when the analysis focuses on the RFS. This apparent discrepancy may 
be explained by the inclusion of non-breast second primary tumors among the 
event of interest for the estimation of IDFS according to the STEEP system (11).  
It is well acknowledged, indeed, that the inclusion of these non-breast cancer 
events for the estimation of the end-point avoids problems that arises from 
misdiagnosing a distant recurrence as a second primary cancer, but it has the 
drawback of diluting any treatment effect, should these second primaries not be 
related to the therapy under study (11).  
In our trial, a small and non-statistically-significant, excess of non-breast 
second primary tumors is reported for the experimental arm. However, if we look 
at the incidence of second cancers across all randomized trials assessing a taxane-
based adjuvant regimen reported in extenso so far, we note that there is overall no 
evidence of excess of non-breast cancer events for the taxane-based arms. 
 Furthermore, it appears that the incidence of non-breast primaries reported in 
our experimental arm is around the average of the other trials, while a very low 
incidence is registered for the control arm in our trial. These figures suggest that 
the imbalance of non-breast cancer events in the Taxit 216 trial  is very probably 
unrelated to the treatment and occurred by chance. Therefore, their inclusion into 
the primary end-point may have weakened the discriminatory power of the 
analysis. In this situation, a better estimate of the therapeutic effect may come 
from the RFS analysis, which appeared, in our trial, significantly improved by the 
addition of docetaxel (about 25% relative risk reduction). Consistently with this, 
the experimental arm also showed a statistically significant advantage in OS 
(about 33% relative risk reduction).    
Several phase III randomized trials have attempted to evaluate the effect of 
taxanes, combined with or in sequence with anthracycline-based regimens, in the 
adjuvant treatment of EBC patients. Most, but not all, the efficacy data so far 
available show a significant reduction of the risk of recurrence for the taxane-
based treatment versus the control anthracycline-based treatment (12-24). On the 
other hand, a benefit in OS has been found only in a few trials (13, 14, 16, 20), 
casting doubts about the worth of such drugs in the adjuvant setting. However, a 
recent meta-analysis of all randomized trials available suggested that on average 
the addition of a taxane to an anthracycline-based treatment yields significant 
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benefits also in terms of OS (25). The final analysis of our trial is consistent with 
this finding lending further support to the use of such drugs, particularly docetaxel, 
in the adjuvant setting. 
Controversy exists as to whether the anthracycline-based control arms in such 
trials could be considered standard control arms. Indeed, not all anthracycline-
based regimens used as control arm in such trials have clearly proven superiority 
versus CMF, thus confounding the interpretation of the results. In such a situation, 
clinical preference should be given to those taxane-based regimens that have been 
compared to an adequate anthracycline-based control regimen.  
The block-sequential E-CMF regimen used as control arm in the Taxit 216 trial 
is among the few control regimens in adjuvant taxane trials, if not the only one, 
that have succeeded on CMF in direct randomized comparisons (6, 7), making its 
results very solid. A similar block-sequential regimen, but with a lower number of 
cycles, has been used as control arm in the recently published BIG2-98 trial (23), 
leading to comparable results.  
A crucial issue is whether taxanes should be combined with anthracyclines or 
whether they should be administered sequentially after an anthracycline-based 
regimen. Both options have theoretical advantages and drawbacks: combination 
regimens require dose-reduction for both compounds but may, in theory, exploit 
drug synergism; in sequential regimens, on the other hand, both compounds can be 
administered at optimal doses. Three decades ago, Norton and Simon reported that 
the growth of solid neoplasms could be described by Gompertzian curves, in 
which the rate of regrowth of a tumor increases as the tumor shrinks in response to 
therapy. The Norton – Simon hypothesis (5) predicted that this resistance might be 
overcome by switching from initial chemotherapy agents to new agents at the 
maximally tolerated dose.  
The results of the Taxit 216 trial are consistent with this hypothesis. Other 
trials, however, have found similar results with regimens in which the taxane was 
given in combination with the anthracycline (14, 18). De Laurentiis et al, in their 
metanalysis of randomized trials (25), carried out an exploratory indirect 
comparison between block-sequential and combination regimens and did not find a 
statistically significant difference between the therapeutic effect of such regimens. 
However, because of the indirect nature of this comparison, it cannot be definitely 
excluded that there could be moderate but worthwhile differences in efficacy 
between these types of regimens, which can only be identified in a direct 
randomized comparison.  
To date, the only trial reporting a direct randomized comparison between a 
sequential and combination taxane-based regimen is the BIG2-98 trial (23), 
showing an advantage for the sequential regimen of borderline statistically 
significance.  However, design issues (ie, the longer treatment duration of the 
experimental arm, the different docetaxel/anthracycline doses, the unplanned 
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nature of this comparison) preclude definitive conclusions about this issue. Results 
of other adjuvant trials, such as BCIRG 005 and NSABP B-30 trials, that are 
testing sequential and concurrent anthracycline-docetaxel regimens, are eagerly 
awaited.  
There is some controversy about whether taxanes produce consistent benefit 
across specific subgroups of patients. Single trial figures suggest that the benefits 
of taxanes may be lower, if not negligible, for N>4+ (14, 20) and for ER+ patients 
(12, 13, 16, 24). Other trials suggest that benefit differs between younger and older 
patients (14, 20, 22).  
In our trial, docetaxel appears to reduce the risk of recurrence irrespective of 
ER status (ER+ vs ER-), nodal status (N1-3 vs N4-9 vs N10+), age (<=50 vs >50) 
and menopausal status (pre-menopausal vs post-menopausal). Although a 
fluctuation of the relative benefit is evident across some subgroups of patients, 
there is  indeed no statistically significant heterogeneity among such estimates, 
thus indicating that this fluctuation only arises by chance. Therefore, our study 
indicates that neither the number of axillary lymph node metastases, or the age, or 
the menopausal status and ER status should be used in clinical practice to identify 
patients who may (or may not) benefit from our experimental regimen. Again, this 
is consistent with what reported on average by the above mentioned metanalysis of 
randomized trial (25).   
Two limitations of our trials deserve discussion. First, in the context of the 
other relevant trials, the Taxit 216 trial is penalized by a smaller than average 
sample size. It may be argued that this decreases the value of the trial results. 
However, underpowered trials have by definition a high chance of not detecting a 
statistically significant difference between treatments (i.e, high chance of being 
false-negative trials). Conversely, once a statistically significant difference is 
detected, as in the case of our trial, the small sample size does not decrease the 
absolute strength of such an evidence, although it affects the precision of the point 
estimate for the HR. Second, our experimental treatment is longer than other 
taxane-based regimens and this may raise concerns as to whether it could cause 
excessive toxicity and patients’ discomfort. 
In this regard, our toxicity analysis appears reassuring. Hematologic severe 
adverse events were rare in our experimental arm except for G3-4 neutropenia. 
However, if we limit the analysis to the day planned for chemotherapy 
administration, severe neutropenia was not more frequent than in the control arm 
and it was inferior to what generally reported with other shorter taxane-based 
regimens (14, 20, 22). Febrile neutropenia affected more patients in the 
experimental arm than in the control arm (11.6% vs 6.2%), but its frequency was 
similar to what reported for shorter block-sequential regimens (20, 22) and much 
less than the 25% reported for the TAC regimen (14). Among other taxane-
specific adverse events, severe neurotoxicity was rare (1%) and its frequency was 
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inferior to what reported for shorter paclitaxel-based regimens (13, 15, 22, 26, 27). 
Furthermore, if patients’ preferences are concerned, recent data indicate that the 
duration of an adjuvant regimen is less important than expected for patients and 
that most of them are willing to accept a longer treatments if this is associated to 
an even marginal additional benefit (28). In this regard, as a balance to the longer 
duration, our regimen is the only one to yield so far an OS benefit in comparison 
to an adequate anthracycline regimen. 
In conclusion, incorporating docetaxel into a block-sequential E-CMF regimen 
yields a significant reduction of the risk of recurrence and death for node-positive 
EBC. This effect is independent of the age and of the menopausal status of the 
patients so as of the ER status of the tumor and the number of axillary lymph node 
metastases. This advantage comes at the cost of an increased, but acceptable, 
toxicity and discomfort. 
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Table 1: Patient characteristics by treatment arm 
 E  CMF (486) E  T CMF (486) 
 
   
 <50 227(46.7) 213 (43.8) 
 Age 
 50 259 (53.3) 273 (56.2) 
 Pre 244 (50.2) 243 (50.0) 
 Menopause 
 Post 242 (49.8) 243 (50.0) 
 1 194 (39.9) 219 (45.1) 
 2 242 (49.8) 203 (41.8)  T 
 3-4 50 (10.3) 64 (13.2) 
 1-3 179 (36.8) 178 (36.6) 
 4-9 193 (39.7) 198 (40.7)  Nodes 
 >=10 114 (23.5) 110 (22.6) 
 Ductal 390 (80.3) 378 (77.8) 
 Lobular 59 (12.1) 71 (14.6)  Histology 
 Other 37 (7.6) 37 (7.6) 
 Negative 114 (23.5) 117 (24.1) 
 Positive 319 (65.6) 315 (64.8)  ER 
 Unknown 53 (10.9) 54 (11.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
Table 2: Reasons for discontinuation of chemotherapy by received 
treatment 
 
Causes of interruption E CMF E  T CMF 
Breast cancer relapse 3 7 
Second primary malignancy 0 1 
Adverse experience 17 31 
Consent withdrawal 12 43 
Death 0 1 
Protocol deviation 0 2 
Lost 0 3 
Other 4 25 
Not Reported 10 14 
   Total      46      127 
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Table 3: Patients with first IDFS events 
 
 E CMF (486) E  T CMF (486) 
   
Breast cancer relapse 139 (28.6) 108 (22.2) 
 Loco\regional 25 (5.1) 19 (3.9) 
 Distant 114 (23.5) 89 (18.3) 
Death 5 (1.0) 7 (1.4) 
Second primary cancer 5 (1.0) 14 (2.9) 
 Breast 1 (0.2) 3 (0.6) 
 Other 4 (0.8) 11 (2.3) 
Total IDFS events 149 (30.7) 129 (26.5) 
None (event-free patients) 337 (69.3) 357 (73.5) 
 
 
 
 
 
 
Table 4: Adjusted Hazard Ratios for different endpoints*  
 
 
Events 
E CMF E  T CMF 
 
HR (95%CI) 
IDFS 149 129 0.82 (0.64-1.03) 
RFS 146 117 0.75 (0.59-0.96) 
OS 85 57 0.67 (0.48-0.94) 
*Adjusted for lymph node metastases, ER status and menopausal status. 
 19 
 
REFERENCES 
 
 1.  Effects of chemotherapy and hormonal therapy for early breast cancer on 
recurrence and 15-year survival: an overview of the randomised trials. 
Lancet 365:1687-1717, 2005 
 2.  Polychemotherapy for early breast cancer: an overview of the randomised 
trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352:930-
942, 1998 
 3.  Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating 
doxorubicin and CMF regimens in breast cancer with more than three 
positive nodes. Ten-year results. JAMA 273:542-547, 1995 
 4.  Buzzoni R, Bonadonna G, Valagussa P, et al.: Adjuvant chemotherapy 
with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in 
the treatment of resectable breast cancer with more than three positive 
axillary nodes. J Clin Oncol 9:2134-2140, 1991 
 5.  Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat 
Rep 70:163-169, 1986 
 6.  De Placido S, De Laurentiis M, De Lena M, et al.: A randomised factorial 
trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs 
chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of 
node-positive breast cancer. Br J Cancer 92:467-474, 2005 
 7.  Poole CJ, Earl HM, Hiller L, et al.: Epirubicin and cyclophosphamide, 
methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N 
Engl J Med 355:1851-1862, 2006 
 8.  Valero V, Holmes FA, Walters RS, et al.: Phase II trial of docetaxel: a 
new, highly effective antineoplastic agent in the management of patients with 
anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 
1995 
 9.  Ravdin PM, Burris HA, III, Cook G, et al.: Phase II trial of docetaxel in 
advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J 
Clin Oncol 13:2879-2885, 1995 
 10.  Nabholtz JM, Senn HJ, Bezwoda WR, et al.: Prospective randomized trial 
of docetaxel versus mitomycin plus vinblastine in patients with metastatic 
 20 
breast cancer progressing despite previous anthracycline-containing 
chemotherapy. 304 Study Group. J Clin Oncol 17:1413-1424, 1999 
 11.  Hudis CA, Barlow WE, Costantino JP, et al.: Proposal for standardized 
definitions for efficacy end points in adjuvant breast cancer trials: the STEEP 
system. J Clin Oncol 25:2127-2132, 2007 
 12.  Buzdar AU, Singletary SE, Valero V, et al.: Evaluation of paclitaxel in 
adjuvant chemotherapy for patients with operable breast cancer: preliminary 
data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002 
 13.  Henderson IC, Berry DA, Demetri GD, et al.: Improved outcomes from 
adding sequential Paclitaxel but not from escalating Doxorubicin dose in an 
adjuvant chemotherapy regimen for patients with node-positive primary 
breast cancer. J Clin Oncol 21:976-983, 2003 
 14.  Martin M, Pienkowski T, Mackey J, et al.: Adjuvant docetaxel for node-
positive breast cancer. N Engl J Med 352:2302-2313, 2005 
 15.  Mamounas EP, Bryant J, Lembersky B, et al.: Paclitaxel after doxorubicin 
plus cyclophosphamide as adjuvant chemotherapy for node-positive breast 
cancer: results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005 
 16.  Fountzilas G, Skarlos D, Dafni U, et al.: Postoperative dose-dense 
sequential chemotherapy with epirubicin, followed by CMF with or without 
paclitaxel, in patients with high-risk operable breast cancer: a randomized 
phase III study conducted by the Hellenic Cooperative Oncology Group. Ann 
Oncol 16:1762-1771, 2005 
 17.  Evans TR, Yellowlees A, Foster E, et al.: Phase III randomized trial of 
doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as 
primary medical therapy in women with breast cancer: an anglo-celtic 
cooperative oncology group study. J Clin Oncol 23:2988-2995, 2005 
 18.  Gianni L, Baselga J, Eiermann W: European Cooperative Trial in Operable 
Breast Cancer (ECTO): Improved freedom from progression (FFP) from 
adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide 
methotrexate and fluorouracil (CMF). (Abs#513). J Clin Oncol 2005 ASCO 
Annual Meeting Proceedings. Vol 23, No. 16S:513, 2005 
 19.  Jones SE, Savin MA, Holmes FA, et al.: Phase III trial comparing 
doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide 
 21 
as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 
2006 
 20.  Roche H, Fumoleau P, Spielmann M, et al.: Sequential adjuvant epirubicin-
based and docetaxel chemotherapy for node-positive breast cancer patients: 
the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006 
 21.  Bear HD, Anderson S, Smith RE, et al.: Sequential preoperative or 
postoperative docetaxel added to preoperative doxorubicin plus 
cyclophosphamide for operable breast cancer:National Surgical Adjuvant 
Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006 
 22.  Martin M, Rodriguez-Lescure A, Ruiz A, et al.: Randomized phase 3 trial 
of fluorouracil, epirubicin, and cyclophosphamide alone or followed by 
Paclitaxel for early breast cancer. J Natl Cancer Inst 100:805-814, 2008 
 23.  Francis P, Crown J, Di Leo A, et al.: Adjuvant chemotherapy with 
sequential or concurrent anthracycline and docetaxel: Breast International 
Group 02-98 randomized trial. J Natl Cancer Inst 100:121-133, 2008 
 24.  Goldstein LJ, O'Neill A, Sparano JA, et al.: Concurrent Doxorubicin Plus 
Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus 
Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary 
Nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin 
Oncol, 2008 
 25.  De Laurentiis M, Cancello G, D'Agostino D, et al.: Taxane-based 
combinations as adjuvant chemotherapy of early breast cancer: a meta-
analysis of randomized trials. J Clin Oncol 26:44-53, 2008 
 26.  Citron ML, Berry DA, Cirrincione C, et al.: Randomized trial of dose-
dense versus conventionally scheduled and sequential versus concurrent 
combination chemotherapy as postoperative adjuvant treatment of node-
positive primary breast cancer: first report of Intergroup Trial C9741/Cancer 
and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 
 27.  Sparano JA, Wang M, Martino S, et al.: Weekly paclitaxel in the adjuvant 
treatment of breast cancer. N Engl J Med 358:1663-1671, 2008 
 28.  Duric VM, Butow PN, Sharpe L, et al.: Comparing patients' and their 
partners' preferences for adjuvant chemotherapy in early breast cancer. 
Patient Educ Couns 72:239-245, 2008 
 
Taxane-Based Combinations As Adjuvant Chemotherapy of
Early Breast Cancer: A Meta-Analysis of Randomized Trials
Michele De Laurentiis, Giuseppe Cancello, Diego D’Agostino, Mario Giuliano, Antonio Giordano,
Emilia Montagna, Rossella Lauria, Valeria Forestieri, Angela Esposito, Lucrezia Silvestro, Roberta Pennacchio,
Carmen Criscitiello, Agnese Montanino, Gennaro Limite, Angelo Raffaele Bianco, and Sabino De Placido
A B S T R A C T
Purpose
We conducted a meta-analysis of randomized trials that evaluated the efficacy of incorporating
taxanes into anthracycline-based regimens for early breast cancer (EBC). We aimed to determine
whether this approach improves disease-free survival (DFS) and overall survival (OS) and whether
benefits are maintained across relevant patient subgroups.
Methods
Studies were retrieved by searching the PubMed database and the proceedings of major
conferences. We extracted hazard ratios (HR) and 95% CIs for DFS and OS from each trial and
obtained pooled estimates using an inverse-variance model.
Results
Thirteen studies were included in the meta-analysis (N  22,903 patients). The pooled HR
estimate was 0.83 (95% CI, 0.79 to 0.87; P  .00001) for DFS and 0.85 (95% CI, 0.79 to 0.91;
P .00001) for OS. Risk reduction was not influenced by the type of taxane, by estrogen receptor
(ER) expression, by the number of axillary metastases (N1 to 3 v N4), or by the patient’s
age/menopausal status. Sensitivity analysis showed that taxanes given in combination with
anthracyclines, unlike sequential administration, did not significantly improve OS. However, the
test for interaction showed that HR did not differ between the two schedules (P  .54). Taxane
administration resulted in an absolute 5-year risk reduction of 5% for DFS and 3% for OS.
Conclusion
The addition of a taxane to an anthracycline-based regimen improves the DFS and OS of high-risk
EBC patients. The DFS benefit was independent of ER expression, degree of nodal involvement,
type of taxane, age/menopausal status of patient, and administration schedule.
J Clin Oncol 26:44-53. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Adjuvant chemotherapy based on combinations
of cytotoxic drugs reduces the risk of recurrence
of radically resected early breast cancer (EBC).
Anthracycline-based combinations are generally
more effective than earlier combinations like
cyclophosphamide-methotrexate-fluorouracil (CMF)
andhavebecome the standard adjuvant chemother-
apy for most patients with breast cancer.1,2
Taxanes have recently emerged as themost ac-
tive cytotoxic agents for breast cancer. In the meta-
static setting, these compounds were active in
anthracycline-resistant disease, and in phase III tri-
als, single-agent taxanes were at least as active as,
and sometimes more active than, single-agent
anthracyclines.3-5 Furthermore, the combination of
anthracyclines and taxanes resulted in a better re-
sponse rate and, in some cases, a longer time-to-
progression than standard anthracycline-based
regimens.6 Consequently, taxane-anthracycline
combinations are nowwidely used as standard first-
line treatment for advanced breast cancer.
The results of the phase III trials prompted
randomized trials designed to evaluate the effect of
taxanes, combined with or in sequence with
anthracycline-based regimens, in the adjuvant treat-
ment of EBC patients. Most, but not all, of the effi-
cacy data published to date show a significant
improvement in disease-free survival (DFS) for the
taxane-based treatment versus the control
anthracycline-based treatment.7-20 Nonetheless, the
role of taxane-based chemotherapy as adjuvant
treatment of EBC remains controversial. For in-
stance, a benefit in overall survival (OS) has been
found only in a few trials.8,10,14,17 In addition, it
remains unclear whether taxane-based regimens
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yieldworthwhile benefits in patientswith four ormore axillarymetas-
tases (N4), because some trials have shown, at subgroup analysis, a
lower or no benefit for such patients.14,17 However, one of the major
issues is whether endocrine-responsive tumors benefit from adjuvant
taxane-based therapy. Most trials carried out so far did not find a
significant benefit in this subgroupof patients7,8,10,16,20; hence, a panel
of internationalbreast cancerexpertsproscribed taxane-based therapy
for endocrine-responsive breast cancers.1 Nonetheless, this apparent
lack of benefit in single trials may well be due to chance or to the low
statistical power of subgroup analyses.
In this scenario, we carried out a meta-analysis of randomized
trials to address questions about the efficacy of adjuvant taxane-based
therapy, particularly in relevant subgroups of EBC patients.
METHODS
The review was conducted according to a predefined written protocol devel-
oped byM.D.L. who also coordinated a discussion among all authors to reach
a consensus about each specific methodologic issue.
Study Identification
Studies were identified by a computerized search of the PubMed data-
base (years 2000 to 2006) using the following text words: “breast cancer and
(paclitaxel or docetaxel).” A computerized search of the abstracts and presen-
tations reported at the Annual Meetings of the American Society of Clinical
Oncology held between 2000 and 2006 or at the San Antonio Breast Cancer
Symposium from 2000 to 2005 was run to identify relevant unpublished
studies. Lastly, all review articles and all cross-referenced manuscripts from
retrieved articles were screened for pertinent studies.
Selection Criteria
To be included in the meta-analysis, retrieved studies had to fulfill the
following inclusion criteria: (1) early breast cancer; (2) adjuvant therapy; (3)
randomized trial comparing a taxane-anthracycline-based regimen with an
anthracycline-based regimen. Studies meeting these criteria were excluded
from the analysis if the retrieved paperwas an earlier report of data updated in
a subsequent article, abstract, or presentation.
Outcomes for Analysis
The main outcomes analyzed were DFS and OS. DFS events included
second primary breast cancers, local or distant recurrences of the original
cancer, or death, unless otherwise specified (Table 1).Thedataof all trialswere
based on the intention-to-treat principle, so they compared all women allo-
cated one treatment with all those allocated the other, irrespective of compli-
ance.Theeffectof the treatment for each single studywas expressedas ahazard
ratio (HR) of the taxane-based arm over the standard anthracycline-based
arm.Thus, anHRgreater thanone favors the standardarmwhereas anHR less
than 1 favors the taxane-based treatment. 95% CIs were calculated for each
point estimate.
Data Extraction
The following informationwas extracted fromeach report: studydesign,
regimen details, allocated patients, nodal status, median follow-up, HRs for
the whole study populations and for major patient subgroups (if available),
and year of reporting. Data were independently extracted from each report by
A.G. and M.G., who were blinded to each other, using a standardized data
recording form.After extraction, datawere reviewedandcomparedbyM.D.L.
and G.C. Instances of disagreement between the two data extractors were
resolved by consultation.
Author-reportedHRswith95%CIswereusedwhenpossible. If 95%CIs
were not directly reported, they were estimated by the P value of the log-rank
statistics.21 For two studies,10,16 reported HRs referred to the standard arm
rather than the taxane-based arm (ie, HR  1 favoring taxanes) and were,
therefore, recalculated by taking the exponential of negative ln(HR) to keep
consistency with other trials. When HRs were not directly reported in the
original study, theywereestimated indirectlyusingeither the reportednumber
of events and the corresponding P value for the log-rank statistics, or by
reading off survival curves as suggested by Parmar et al.21 To reduce reading
errors, original survival curves were digitalized and enlarged, and data extrac-
tionwas based on reading off electronic coordinates for each point of interest.
Data Synthesis
A pooled estimate of the HRs was computed by a fixed-effect model
according to the inverse-variance method.22 We also used the DerSimonian
and Laird23 random-effect model. This gives a more appropriate estimate of
the average treatment effect when trials are statistically heterogeneous, and it
usually yields wider CIs, thereby resulting in a more conservative statistical
claim. Homogeneity assumption was checked with Cochran’s Q statistics.24
Toobtainaquantitativemeasureof thedegreeof inconsistency in the resultsof
studies, we calculated a Higgins’ I2 index. This index describes the percentage
of total cross-study variation that is due to heterogeneity rather than
chance.25 Potential publication bias was estimated with the Begg-
Mazumdar test26 and the Egger test.27 For all the analyses, a forest plot was
generated to display results.
We carried out a sensitivity analysis by recalculating the pooled HR
estimate for different subsets of studies basedon relevant clinical features. This
analysis serves todeterminewhether thepooledestimates are stableorwhether
they depend on some features of the studies included in the meta-analysis.
Consequently, it showswhether ornot the overall resultwouldbe affectedby a
change in the meta-analysis selection criteria.
A subgroup analysis was performed by pooling estimates for similar
subsets of patients across trials where available. An interaction test between
treatment effect and subgroup factors was calculated according to Deeks et
al.28Toestimate theabsolutegains inDFSandOS,wecalculatedmeta-analytic
survival curves as suggested by Parmar et al.21 All statistical calculations were
done by computer routines developed in-house.
RESULTS
Results of Literature Search
Fourteen studies were identified.7-20 Of these, the US Oncology
study by Jones et al18 was excluded because it investigated the role of a
taxane insubstitutionof(andnot inadditionto)ananthracycline.There-
fore, 13 studies were used in the main pooled analysis (22,903 patients).
Table 1 presents the studies identified and their main characteristics.
Overall Effect of Taxanes on Risk of Recurrence
HRs forDFSwere available, either directly or indirectly, for all 13
studies accounting for 5,829 events. Single-study HRs ranged from
0.63 to 0.97 and were statistically significant in seven studies. Figure 1
reports the estimated pooled HR for all studies. The reduction of risk
of recurrencewas highly significant (P .00001) in patients receiving
taxane-based therapy, and there was no significant difference regard-
ing the type of taxane administered (test for interaction, P .16). In
addition, there was no evidence of heterogeneity among trials (P 
.32; I2 12.1%) or publication bias (Begg-Mazumdar test, P .14;
Egger test, P .08). The sensitivity analysis (Table 2) shows that DFS
was significantly improvedevenwhen themeta-analysiswas restricted
to trials of taxanes in combination regimens, to trials of taxanes in
sequential regimens, or to studies of node-positive patients only.
Overall Effect of Taxanes on the Risk of Death
One study7 did not reportOS data, and thus themeta-analysis of
the effect of taxanes on the risk of death is limited to 12 studies and
22,379patients, accounting for 3,329deaths. Single-studyHRs ranged
from 0.41 to 1.03 andwere statistically significant in four studies. The
estimated pooled HR for all the studies shows a highly significant
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Table 1. Main Characteristics of the Studies Included in the Meta-Analysis
Trial
N
Status
No. of
Patients
Median
FU2
(months)
Author-Reported Data
Notes
DFS OS
Rate P 95% CI Events Rate P 95% CI Deaths
M.D. Anderson (MDACC2002)7
2002
N-/N 524 60 0.70 .09 0.47 to 1.07 NR Primary end point is RFS,
but its definition is not
reported
Design
-F500 A50 C500  8 259 53
-P250  4- F500A50
C500  4
265 39
CALGB 93448 2003† N 3,121 69 0.83 .0013 0.73 to 0.94 0.82 .0061 0.71 to 0.95 DFS does not include
second breast
primaries
Design
-A(diff.doses)C  4 1,570 563 400
A(diff.doses)C  4-
P175  4
1,551 491 342
Anglo-Celtic15 2005 N-/N 363 32 NR NR Primary end point is RFS
(relapse-free survival),
but its definition is not
reported
Design
-A60 C600  6- S 180 55 28
-A60 D75  6- S 183 45 25
BCIRG 00114 2005 N 1,491 55 0.72 .001 0.59 to 0.88 0.70 .008 0.53 to 0.91 DFS includes also second
nonbreast primaries
Design
-F500 A50 C500  6 746 227 130
-D75 A50 C500  6 745 172 91
ECOG E 219716 2005 N-/N 2,885 59 1.03 .70 0.86 to 1.25 1.09 .49 0.85 to 1.40 Data are from oral
presentation. Author
reported HRs are for
taxane-based arm over
control arm (HR 1
favors taxanes)
Design
-A60 C600 x 4 1,441 219 125
-A60 D600 x 4 1,444 213 117
ECTO11 2005‡ N-/N 1,355 43 0.65 .01 0.47 to 0.90 0.71 .16 NR Data are from oral
presentation and
pertain to Cox analysis.
Primary end point is
freedom from
progression (FFP)
defined as the interval
from random
assignment to first
evidence of breast
cancer progression or
relapse
Design
A-A60 x 4- CMF  4 453 91 41 Events and Deaths: Arm
B v Arm A
B-A60 P200 x 4- CMF  4 451 63 30 Events and Deaths: Arm
B v Arm A
C-A60 P200  4- CMF 
4-S
451 78 32 Events and Deaths: Arm
B v Arm A
GEICAM 990613 2005 N 1,248 46 0.63 .001 0.48 to 0.83 0.74 .14 NR HR are from Cox
analysis; DFS definition
not reported
Design
-F600 E90 C600  6 634 128 49
-F600 E90 C600 x 43 P100
 8 wks
614 83 34
HeCOG 10/9710 2005¶ N-/N 595 62 1.16 .31 0.87 to 1.55 2.42 .02 1.17 to 4.99 HR are from Cox
analysis; author-
reported HRs are for
taxane-based arm over
control arm (HR  1
favors taxanes)
Design
-E110  4-°CMF  4 298 98 61
-E110  3-P250  3-
°CMF  3
297 91 53
NSABP B2812 2005 N 3,059 64.6 0.83 .006 0.72 to 0.95 0.93 .46 0.78 to 1.12 DFS includes second
nonbreast primaries
Design
-A6 0C600  4 1,531 463 255
-A60 C600  4- P225  4 1,528 400 243
(continued on following page)
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reduction of the risk of death for patients receiving a taxane-based
therapy (P  .0001; Fig 2). There was no statistical heterogeneity
among studies (P .10; I2 36.2%) or evidence of publication bias
(Begg-Mazumdar test,P .27;Egger test,P .19).The improvement
in OS was similar for the paclitaxel group and for the docetaxel
group (test for interaction, P .55). The sensitivity analysis (Table 2)
shows thatOSwas not significantly improvedwhen themeta-analysis
was restricted to studies of combination regimens, and there was
significant heterogeneity among trials (P .02).However, the test for
interaction (P .54) indicates that the risk reductionobserved for this
subset of studies was not significantly different from that observed for
studies of sequential regimens.
Effect of Taxanes in Specific Subgroups of Patients
Because of lack of information in most trials, subgroup analysis
according toestrogenreceptor (ER) status (ERpositive vERnegative),
nodal status (N1 to 3 v N4), age ( 50 v 50), menopausal status
(premenopausal v postmenopausal) and HER-2 status (HER-2 posi-
tive v HER-2 negative) was possible only for subsets of trials and only
for DFS. Treatment effect according to ER status was available, either
directly reported or indirectly derived, for 10 studies and a total of
17,324 patients. Pooled HR estimates indicate that taxanes signifi-
cantly reduced the risk of recurrence for both ER-positive and ER-
negative patients (Fig 3). There was indeed no statistically significant
difference between the HRs in the two patient subgroups (test for
interaction, P .31). This was independent of whether paclitaxel or
docetaxel was administered (data not shown). HR estimates by nodal
status were available for four trials and 6,179 patients. The pooledHR
forDFSwas similar forpatientswithone to threepositive lymphnodes
and for patients with four or more positive lymph nodes (test for
interaction, P .63; Fig 4).
Treatment effect according to age/menopausal status is reported
in Figure 5. Only three trials reported DFS information based on age
grouping (50 v50years), and twoother trials reporteddatabased
on menopausal status. Because postmenopausal status usually arises
Table 1. Main Characteristics of the Studies Included in the Meta-Analysis (continued)
Trial
N
Status
No. of
Patients
Median
FU2
(months)
Author-Reported Data
Notes
DFS OS
Rate P 95% CI Events Rate P 95% CI Deaths
BIG 2-9820 (TAX-315) 2006§ N 2,887 62.5 0.86 .051 0.74 to 1.00 0.92 .34 0.75 to 1.13 Data are from oral
presentation
(Arm 3  Arm 4 v
Arm 1  Arm 2)
(Arm 3  Arm 4 v
Arm 1  Arm 2)
DFS definition not
reported
Design
1-A75  4- CMF  3 481 266 143
2-A60 C600  4- CMF  3 487
3-A75  3-D100  3-
CMF  3
960 466 260
4-A50 D75  4- CMF  3 959
NSABP B279 2006 N-/N 2,404 77.9 0.90 .24 0.76 to 1.06 1.08 .51 NR DFS includes also all
clinically inoperable,
residual disease at
surgery, and second
nonbreast primaries;
Arm III v Arm I
Design
I-A60 C600  4- S 802 276 157
II-A60 C600  4-D100 
4- S
803 260 156
III-A60 C600  4- S-D100
 4
799 254 171
PACS 0117 2006 N 1,999 60 0.82 .034 0.69 to 0.99 0.73 .014 0.56 to 0.94 Data are from oral
presentation and
pertain to Cox analysis;
DFS definition not
reported
Design
-F500 E100 C500  6 1,003 264 130
-F500 E100 C500  3-
D100  3
996 218 135
TAXIT 21619 2006 N 972 53.6 0.79 .058 0.61 to 1.00 0.72 .08 0.5 to 1.04 Data are from oral
presentation; DFS
includes second
nonbreast primaries
Design
-E120  3-CMF  3 486 138 70
-E120  3- D100  3-
CMF  3
486 115 51
NOTE. Both arms and all drugs q14.
Abbreviations: P, paclitaxel; D, docetaxel; E, epidoxorubicin; A, doxorubicin; S, surgery; NR, not reported, DFS, disease-free survival, OS, overall survival; RFS,
relapse/recurrence-free survival; HR, hazard ratio.
M.D.Anderson: fluorouracil: days 1,4; doxorubicin, 72 hours continuous infusion; paclitaxel, 24 hours continuous infusion.
†CALGB 9344: A (differing doses): adriamicin 60, 75, or 90 mg/m2.
‡ECTO CMF: cyclophosphamide, 600 mg/m2; methotrexate, 40 mg/m2; fluorouracil, 600 mg/m2 days 1,8 q28.
§HeCOG 10/97 CMF: cyclophosphamide, 840 mg/m2; methotrexate, 57 mg/m2; fluorouracil, 840 mg/m2.
TAXIT 216 CMF: cyclophosphamide: 600 mg/m2; methotrexate, 40 mg/m2; fluorouracil, 600 mg/m2 days 1,8 q28.
¶BIG 2-98 CMF: cyclophosphamide 100 mg/m2 PO days 1-14; methotrexate, 40 mg/m2 fluorouracil, 600 mg/m2 days 1,8 q28.
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around the age of 50 years, these two groupings are partially inter-
changeable, and we analyzed them together to obtain a more precise
estimate. Taxanes resulted in a significant risk reduction for both age
 50 years/premenopausal and older than 50 years/postmenopausal
patients. The large benefit observed in the older group in the Spanish
Breast Cancer Research Group (GEICAM) trial resulted in statistical
heterogeneity. However, there is no statistically significant difference
between the HRs for the two subgroups of patients (test for interac-
tion, P .13). Results were similar when the analysis was restricted to
age grouping (data not shown). Only two studies reported DFS data
according to HER-2 expression, and, therefore, HR estimates are less
reliable (Fig 6). However, there was no interaction between HER-2
expression and taxane administration in terms of reduction of risk of
recurrence (test for interaction, P .28).
Absolute Benefits of Taxane Therapy
Figure 7 depicts metacurves of DFS and OS derived from strati-
fied pooling of the data of the trials. Cumulative estimates of proba-
bility of DFS and OS are drawn up to 5 years. Estimates became
unreliable beyond this timebecause follow-up is still immature. Based
on these curves, the estimated absolute risk reduction at 5 years,
gained by adding a taxane to an anthracycline-based adjuvant regi-
men, is approximately 5% for DFS and 3% for OS.
DISCUSSION
We identified 13 studies that assessed the addition of a taxane to
an anthracycline-based regimen. These studies accounted for a
total of 22,452 randomly assigned women, 5,829 recurrences,
and 3,329 deaths. These data are sufficient to provide reliable
evidence to endorse or to confute the use of these drugs as
adjuvant treatment for EBC. However, interpretation of such a
large quantity of data is a challenging task for the average
oncologist because single trials may report conflicting results.
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Fig 1. Meta-analysis of disease-free sur-
vival (DFS). Studies are grouped based on
the type of taxane used. Within each
group, trials are ordered by year of report-
ing and by alphabetical order; squares on
the hazard ratio plot are proportional to the
weight of each study; weighting is based
on the inverse variance method.
Table 2. Sensitive Analysis for Some Relevant Groups of Studies
DFS OS
No. of
Patients
Fixed Effect Random Effect
Test of
Heterogeneity P
No. of
Patients
Fixed Effect Random Effect
Test of
Heterogeneity PHR 95%CI HR 95%CI HR 95%CI HR 95%CI
Combination trials 7,540 0.84 0.76 to 0.93 0.84 0.73 to 0.96 .14 7,540 0.89 0.79 to 1.02 0.84 0.67 to 1.06 .02
Sequential trials† 15,363 0.83 0.78 to 0.88 0.83 0.78 to 0.88 .39 14,839 0.86 0.79 to 0.93 0.83 0.74 to 0.94 .09
N only trials‡ 14,777 0.81 0.76 to 0.86 0.81 0.76 to 0.86 .47 14,777 0.83 0.76 to 0.90 0.83 0.76 to 0.90 .44
Abbreviations: DFS,disease-free survival; OS, overall survival; HR, hazard ratio; ETO; BCIRG;ECOG; CALGB; PACS; GEICAM; HeCOG; NSABP; BIG; TAXIT.
Anglo-Celtic, BCIRG-001, ECOG E2197, ECTO, BIG2-98 (AT v AC).
†M.D. Anderson, CALGB B9344, PACS 01, GEICAM9906, HeCOG, NSABP B28, BIG 2-98 (A-T v A), NSABP B27, TAXIT 216.
‡CALGB B9344, PACS 01, BCIRG-001, GEICAM 9906,NSABP B28, BIG 2-98, TAXIT 216.
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I
This is particularly true when we attempt to derive efficacy
estimates in clinically relevant subgroups of patients. Indeed,
this exercise can probably produce spurious results (either
false-negative or false-positive) for each single trial just because
of chance. In such a situation, meta-analyses may help resolve
controversial issues because they give more accurate (ie, with
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narrower CIs) estimates of the average effect of a treatment, and
also because they help identify causes of statistical heterogeneity
among data (ie, single trials or specific subgroups of patients in
which the observed treatment effect does not appear to be
compatible with the average overall treatment effect).
In the attempt to evaluate the efficacyof the taxane-anthracycline
combination in EBC cancer treatment, we extracted HRs from
relevant trials and performed a meta-analysis of all available data.
Specifically, we aimed to: (1) give the best estimate of the relative
reduction of risk of recurrence and death; (2) give the best estimate of
the magnitude of benefit in terms of absolute reduction of the risk of
recurrence and death; and (3) verify whether or not such benefits
remain consistent across some relevant subgroups of patients. We
used data from trials published in extenso and from trials reported at
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meetings to minimize publication bias. The results of the Begg-
Mazumdar test andof its regression equivalent indicate the absence of
publication bias in our analysis.
Our meta-analysis shows that the addition of a taxane to an
anthracycline-based regimen results in a statistically significant reduc-
tion of the risk of relapse (approximately 17% relative reduction) and
death (approximately 15% relative reduction) for high-risk EBC pa-
tients. These benefits are also clinically relevant since they correspond
to an absolute risk reduction at 5 years of approximately 5% for
recurrence and 3% for death. To put these data in context, anthracy-
clines became the gold standard adjuvant treatment for EBCwhen, in
the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG),
meta-analysis showed an absolute risk reduction at 5 years of approx-
imately 3% both for DFS and OS.2
A crucial issue is whether taxanes should be combined with
anthracyclines or whether they should be administered after an
anthracycline-based regimen. Both options have theoretical advan-
tages and drawbacks: combination regimens require dose-reduction
for both compounds, but may, in theory, exploit drug synergism. On
the other hand, in sequential regimens, both compounds can be ad-
ministered at optimal doses. Comparing these two approaches was
not an aim of this meta-analysis, making the conclusions about this
point speculative. However, due to the importance of the findings, it
merits some discussion. Our sensitivity analysis shows that only se-
quential regimens yielded a statistically significant improvement of
both DFS andOS. Conversely, with combination regimens, the trend
to OS improvement was not significant, and there was statistical het-
erogeneity among trials. However, this result should be interpreted
with caution because the test for interaction indicates that the differ-
ence between the pooled HRs of the two regimens may well be as-
cribed to chance. In this situation, the best HR estimate for both
schedules remains that which was observed in the overall meta-
analysis (Figs 1 and 2). Yet, because such results pertain to indirect
comparisons,we cannot exclude that there could still bemoderate but
worthwhile differences in efficacy between these types of regimens,
which can only be identified in a direct randomized comparison.
There is some controversy about whether taxanes produce con-
sistent benefit across specific subgroups of patients. Single trial figures
suggest that the benefits of taxanesmay be lower, if not negligible, for
N414,17 and for ER-positive patients.7,8,10,16,20 Other trials suggest
that benefit differs between younger and older patients.13,14,17 We
were able to derive pooled estimates for these subgroups, although
relevant data were available only for a subset of trials. We show that
taxanes significantly reduce the risk of recurrence irrespective of ER
status (ER positive v ER negative), nodal status (N1 to 3 v N4), and
age/menopausal status ( 50 years/premenopausal v  50 years/
postmenopausal), and that the magnitude of the relative benefit is
approximately constant across such subgroups of patients. There-
fore age, menopausal status, and ER status should not be used in
clinical practice to identify patients who may not benefit from a
taxane-based regimen.
Like all studies based on aggregated data, ourmeta-analysis, does
not reach the level of evidence obtainable with a meta-analysis based
on individual patient data (IPD) because: (1) it is impossible to deter-
mine the appropriateness of random assignment procedures; (2) trial
heterogeneitycanonlybe statistically tested,butneververified; and(3)
it is not possible to do an intention-to-treat analysis because data
from excluded patients cannot be retrieved. However, in our case,
all authors declared their data were based on the intention-to-treat
principle. In this respect, the EBCTCG is currently obtaining IPD
fromtrials exploring the roleof adjuvant taxane-based treatment.This
will result in amore unbiased pooled analysis and in a finer andmore
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comprehensive subgroup analysis. Nonetheless, provided a rigorous
methodology is used, pooling aggregated data, as in our case, yields
information that is far superior to the simple tally of positive and
negative trials. As opposed to IPDmeta-analysis, the simpler method
we used has the advantage of speed, which is especially important
when relevant clinical questions are pending. While awaiting the de-
finitive results of the EBCTCG overview, our meta-analysis offers the
most comprehensive insight into taxane-basedadjuvant regimensand
may help physicians and their patients worldwide to make a better
informed decision regarding the most appropriate adjuvant therapy.
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